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Aims/Objectives: This thesis aims to explore the interplay between type two 
diabetes mellitus (T2DM) and prostate cancer (PCa) with regards to treatments of 
both conditions and disease outcomes.  
Background: PCa and T2DM are both increasingly prevalent conditions, meaning 
that they often occur together. However, the relationship between the two is 
complex.  
Plan of investigation/Methods: To investigate the complex interplay between the 
two, the thesis was divided into the following projects: 
(1) Using data from Prostate Cancer data Base Sweden (PCBaSe) Sweden this 
thesis investigated:  
i) the impact of co-existing T2DM on receiving curative treatment for 
PCa 
ii) the impact of a PCa diagnosis on T2DM treatment  
iii) how the type and duration of  androgen deprivation therapy (ADT) 
may affect risk of getting T2DM 
(2) Evaluation of whether presence of T2DM and other components of the 
metabolic syndrome (MetS) affects response to ADT using data from patients 
enrolled in the STAMPEDE trial 
(3) Assessment of which tumour components are affected by metformin through a 
randomised controlled trial, METAL (Metformin And Longevity). 
Results:  Men with T2DM were 20% less likely to receive curative treatment for 
intermediate and high risk PCa compared to those without T2DM after adjusting for 
age, co-morbidity and tumour characteristics.  Moreover, men with pre-existing 
T2DM were at increased risk of needing treatment escalations following a PCa 
diagnosis, particularly those treated with ADT.  An increased risk of T2DM following 
treatment with ADT was also shown in which the duration and type of ADT received 
was important. Finally, baseline metabolic aberrations, including T2DM, in men 
commencing ADT for advanced PCa increased the risk of local and metastatic 
progression. 
Conclusion:  This thesis highlights the complexity of the interplay between T2DM 
and PCa, in which both conditions impact on both the treatment and disease 
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Chapter I- Introduction and Research Objectives  
 
Prostate cancer (PCa) is the most common cancer in men, with over 40,000 men 
diagnosed each year in the UK (1). There are also 3.2 million people in the UK who 
have been diagnosed with Type Two Diabetes (T2DM) and it is estimated that this 
will rise to 5 million by 2025 (2). It is therefore clear that both PCa and T2DM are 
prevalent conditions, meaning that they often occur together in the same individual. 
However, the relationship between the two is much more complex than two 
prevalent conditions which just concurrently occur in men. This thesis explores the 
complex interplay between T2DM and PCa with regards to treatments of both 
conditions and disease outcomes.  
More specifically, this thesis is divided into the following chapters: 
Before explaining the different research projects enclosed in this thesis, Chapter II 
covers the relevant background to this thesis and describes the biology, descriptive 
epidemiology, risk factors, clinical management and treatment of PCa, T2DM and 
MetS.  Next, Chapter III systematically reviews the existing literature exploring the 
interplay between T2DM and PCa. It specifically covers the impact of pre-existing 
T2DM on PCa incidence, the impact of pre-existing T2DM on PCa grade and stage, 
the impact of pre-existing T2DM on PCa outcomes and mortality, and the 
interaction between T2DM and PCa treatments.    
Chapter IV uses data from Prostate Cancer data Base Sweden (PCBaSe) Sweden 
and reports on:  
i) The impact of co-existing T2DM on receiving curative treatment for PCa 
ii) The impact of a PCa diagnosis on T2DM treatment  
iii) How the type and duration of androgen deprivation therapy (ADT) may 
affect the risk of getting T2DM 
Chapter V evaluates whether presence of T2DM and other components of the 
metabolic syndrome (MetS) affect response to ADT in advanced PCa using data 
from patients enrolled in the Systemic Therapy for Advancing or Metastatic Prostate 
Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. 
Chapter VI assesses which tumour components are affected by metformin through 
designing, setting up and running a randomised controlled trial investigating the 
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biological effects of metformin in localised PCa – METAL (Metformin And 
Longevity) trial. 
Finally, Chapter VII summarises the overall findings of this thesis before discussing 




Chapter II – Background 
 
This chapter will describe the biology, descriptive epidemiology, risk factors, clinical 
management and treatment of PCa, T2DM and MetS, where appropriate.   
Prostate cancer biology  
The normal prostate 
The prostate gland is a large accessory gland of the male reproductive system. It 
has important functions in the production of spermatozoa including the secretion of 
enzymes which are necessary for their normal functioning (3).  It is a walnut shaped 
gland of approximately 4cm in health (4). Anatomically it sits between the penis and 
the bladder surrounding the neck of the bladder and pre-prostatic portion of the 
urethra (5) (Figure 1). The gland consists of anterior, median, right and left lateral 
and posterior lobes. It can also be divided into several zones. The central zone 
surrounds the ejaculatory duct, whilst the peripheral zone provides the bulk of the 
gland.  There is also a transitional zone which surrounds the prostatic urethra (4) 
(Figure 2).  
 
Histologically there are two distinct areas within the prostate: the glandular 
epithelium and the stromal compartment. Within the glandular epithelium there are 
luminal and basal cells, with occasional neuroendocrine cells. The stromal 
compartment contributes at least half of the volume of the gland and is formed of a 




















Prostate cancer histopathology 
Adenocarcinoma accounts for 95% of PCa and its diagnosis is based on a 
constellation of architectural and cytological appearances, though it can be difficult 
to make the diagnosis because the appearances are subtle (6). Adenocarcinoma 
arises from the glandular epithelial cells and can be seen as small infiltrating glands 
with prominent nuclei. These tumour cells have darker purple cytoplasm on 
hematoxylin and eosin (H&E) stained sections than benign cells. Other cytological 
features of malignant glands include intraluminal crystalloids and blue-tinged mucin. 
The remaining 5% of PCa include neuroendocrine and urothelial (transitional cell) 
carcinomas, which are not discussed here as they are beyond the scope of this 
thesis.  
 
The Gleason Grading system was devised by Donald Gleason in 1996 and is based 
upon the architectural appearance of the PCa. Both the primary pattern and second 
most common pattern are identified and are given a score of 1-5.  These are then 
added together to give a Gleason Sum Score. In practice grade 1 and 2 are not 
used, so most grading begins at 3 (Figure 3). This grading system has been 
universally adopted  and remains the most useful tissue based prognostic tool in 
PCa (4).  
 
More recently a Gleason Grade Group system has been developed consisting of 5 
groups (Figure 3):  
Grade group 1: Gleason score ≤6 
Grade group 2: Gleason score 3+4 = 7 
Grade group 3: Gleason score 4+3 = 7  
Grade group 4: Gleason score = 8 
Grade group 5: Gleason scores = 9-10 
 
The grade group system was validated in an analysis of over 20,000 patients 
undergoing radical prostatectomy. There was an increasing risk of biochemical 
recurrence (BCR) and prostate cancer mortality with increasing grade (7) . In 2014 
this new Gleason Grade Group was accepted at the International Society of 











Prostate Cancer Descriptive Epidemiology  
Worldwide 
PCa is the second most common cancer worldwide in men. In 2012 it is estimated 
that it accounted for 15% of all cancers diagnosed in men with 1.1 million cases.  
Incidence rates vary geographically by more than 25 fold (Figure 4). 70% of cases 
occur in the developed world, with highest rates in Australasia and North America. 
The lowest rates are seen in East and South Central Asia. Higher rates in certain 
less developed regions, including the Caribbean and Southern Africa, probably 
reflect ethnic differences rather than differences in prostate specific antigen (PSA) 
testing and health care systems.  However, rates are rising in the developing world, 
which is likely as a result of increasing westernisation of dietary and lifestyle factors 
in those areas.  Though incidence rates vary widely, mortality rates are more 
constant worldwide. PCa accounts for 6.6% of total deaths in men and is estimated 
to have caused 307,000 deaths worldwide in 2012. The highest mortality rates are 
seen in the predominantly black populations of the Caribbean and Southern Africa 
as compared to Caucasian populations (10).  
United Kingdom  
In the UK PCa is the commonest cancer in men, with approximately 1 in 8 men 
affected.  More than 47,000 men are diagnosed each year and over 330,000 men 
are living with PCa.  There are more than 11,000 deaths per year from PCa (11). 
The standardised death rate (SDR) per 100,000 inhabitants was 47.6 in the UK in 
2013 (12). 
Sweden and the rest of Europe 
It is estimated that there were over 72,000 deaths from PCa across Europe in 2013. 
This accounts for 5.6% of all cancer deaths. Table 1 shows the number of deaths 
and SDR for PCa across European countries. In Sweden the SDR for PCa for all 
men was 62.5, which is higher than in the UK. Sweden is also the only European 



















Prostate Cancer Risk Factors 
There are modifiable and non- modifiable risk factors for PCa. Of the established 
risk factors the most important are all non-modifiable and include: age, 
race/ethnicity and family history/genetic factors. These and some potentially 
modifiable risk factors are discussed below. 
Age 
Like many adenocarcinomas, PCa is strongly associated with increasing age. It is 
seldom diagnosed in men under the age of 40 and its incidence increases 
exponentially from the age of 55. In populations with widespread access to PSA 
testing the average age of PCa diagnosis has shifted forwards, by as much as 10 
years. For example, in the USA the median age at diagnosis is 66 years (4).  
Race/Ethnicity  
PCa incidence and mortality rates vary between different ethnicities, with the 
highest rates seen in black populations. In SEER data from the USA, mortality rates 
in black men were nearly 2.5 times higher than in white men. The lowest incidence 
and mortality rates are seen in Asian populations (4). The average age at diagnosis 
is also lower in black men compared to white men (13). The reasons for these racial 
differences are not fully understood, but are likely to be due to a combination of 
genetic and socioeconomic factors. 
Family History and Genetics  
Several large family and twin studies have established that family history is a 
significant risk factor for PCa. The risk increases with increasing number of family 
members affected.  A Swedish study of in 51,897 men who were brothers of 32,807 
index cases reported that the overall risk of developing PCa for men with one 
brother with PCa by age 65 years was 14.9 vs. 4.8 % in those without a brother with 
PCa, and 30.3 vs. 12.9 % at age 75 years (14).  Several studies have also shown 
that it is not only incidence which clusters in families, but outcomes too (15, 16).  
Hemminki et al. examined the survival in sons according to the fathers' length of 
survival. The hazard ratio (HR) was 0.62, 95% CI: 0.41-0.94 for sons whose fathers 
had survived longer than 59 months, compared with sons whose fathers had 
survived fewer than 24 months.  This suggests that family history also affects PCa 
survival. 
Many genetic factors which may contribute to this familial clustering have now been 
described, but there is no single genetic susceptibility locus or mutation which 
accounts for the majority of familial cases. Multiple genome-wide association 
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studies (GWAS) have been conducted to identify common single nucleotide 
polymorphisms (SNPs) associated with PCa incidence, with more than 100 
candidate loci identified (17).  However, taken together these SNPs only account for 
approximately 1/3 of familial PCa cases (4). Germline mutations in both the 
HOXB13 and BRCA genes have also been shown to be associated with increased 
risk of PCa (18, 19).  Detailed discussion of these mutations is outside of the scope 
of this thesis. 
Diet, Obesity, Activity  
Several dietary factors which have anti-oxidant properties have been shown in 
epidemiological studies to be potentially protective against PCa. These include 
selenium, vitamin E and lycopene, however data from randomised controlled trials 
(RCT) into their use as preventative agents is lacking (20).  An increased risk of 
PCa with calcium and dairy products has been suggested by some, but not all 
studies. One meta-analysis by Gao et al. showed a small increase in risk in the 
highest intake groups of both dairy products and calcium (Relative risk (RR): 1.11, 
95% CI: 1.00 to 1.22 and RR: 1.39, 95% CI: 1.09 to 1.77) (21). The relationship 
between PCa and Vitamin D has also been examined but remains unclear, with 
both high and low levels being associated with increased risk in some studies (4).  
The relationship between obesity and PCa is complex and has been much studied. 
It is established that obesity is not only associated with a small increased risk of 
PCa incidence, but also with PCa aggressiveness and outcomes following 
treatment (22).  Some of this association may be explained by difficulties 
diagnosing and treating obese men, but several biological mechanisms could also 
explain these associations (Figure 5). These include hyperinsulinaemia, increased 
insulin-like growth factor- 1 (IGF-1) levels, changes in sex hormone levels and 
chronic sub-clinical inflammation.  Chronic inflammation results in a host of changes 
including altered levels of adiopokines, including leptin. Leptin levels are raised in 
obesity and have been shown in pre clinical data to increase risk of PCa. However, 
the epidemiological evidence does not demonstrate a consistent positive 
association (22). Chronic inflammation also alters the cytokine microenvironment, 
including increasing levels of IL-6, which has also been linked to increased risk of 
PCa (22).  Furthermore, physical activity has been associated with an inverse risk 
of advanced PCa in several North American cohort studies (23, 24).  The health 
professional’s follow-up study reported no overall association between PCa 
incidence and total, vigorous or non-vigorous physical activity.  However, in all age 
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groups, men with high levels of physical activity were less likely to be diagnosed 
with high-grade (Gleason score ≥7) PCa (24). 
Others 
Smoking has been associated with PCa mortality. The largest meta-analysis 
examining this association included 51 studies and reported an increased risk of 
PCa death in current smokers (RR: 1.24, 95%CI: 1.18-1.31) as well as a dose 
response, with heavier smokers having the highest risk (25).  This suggests that the 
multiple carcinogenic compounds included in tobacco accumulate with heavier use 
and therefore risk increases with increasing exposure.  
Coffee consumption has been shown to be associated with a decreased risk of 
lethal PCa. The health professionals follow up study reported a significant inverse 
association (RR: 0.82, 95% CI: 0.68 -0.98) after adjustment for age, BMI, physical 
activity, smoking, family history and dietary factors . The association appears to be 
related to non-caffeine components of coffee, as it was seen in those drinking both 
caffeinated and decaffeinated coffee (26).   
High levels of alcohol intake have been associated with an increased risk of 
aggressive PCa (RR: 2.01, 95% CI: 1.33-3.05) after adjustment for age, race amd 





Figure 5: Biologic mechanisms contributing to the association between obesity and PCa 
(22) 
 
Prostate Cancer Clinical Management and Treatment  
Screening 
PSA is a protein secreted by the prostate gland which increases with age, size of 
the prostate and also in PCa.  Screening for PCa using PSA measurements has 
been investigated in several large screening trials and remains controversial (28-
30). Current international guidelines do not recommend population based PSA 
screening, as although it reduces PCa mortality (31), this is at the cost of over-
diagnosis and over treatment (32). 
Symptoms and diagnosis  
The majority of PCa is diagnosed following a prostate biopsy prompted by the 
finding of a raised PSA or an abnormal digital rectal examination (DRE), as most 
men with early stage PCa are asymptomatic. Men can sometimes present with 
lower urinary tract symptoms, such as urinary frequency, urgency or nocturia. Less 
commonly, men can present with haematuria or in advanced disease with bone 
pain related to metastatic disease.  
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A transrectal or transperineal prostate biopsy with ultrasound guidance is the gold 
standard diagnostic technique, but should only be undertaken after considering 
DRE ﬁndings, ethnicity, age, co-morbidities, PSA values, free/total PSA, history of 
previous biopsy (32). 
Staging  
If the patient’s co-morbidities and general health do not preclude it, further staging 
investigations should be performed. PCa is staged according to the AJCC TNM 
staging (Figure 6). Localised PCa should then be classified as low, intermediate 
and high risk disease (Table 2). Multi-parametric magnetic resonance imaging 
(MRI) is an important staging investigation in localised disease to allow an accurate 
T stage to be obtained. Those with intermediate or high risk disease should also 
have further investigation with a combination of a technetium  bone scan, positron 
emission tomography-computerized tomography (PET-CT) or whole body MRI to 
assess for the presence of metastatic disease (32). 
Treatment  
Management of localised disease 
There are several treatment options available for those with localised disease and 
at present there is no consensus as to which should be the preferred approach. 
Instead, treatment options are discussed with patients and management is tailored 
to their individual needs and preferences.  
 
For both low and intermediate risk localised disease, active surveillance (AS) is an 
option.  This consists of close monitoring, using a combination of PSA, MRI and 
repeat biopsies. There is currently no internationally recognised optimal schedule 
for AS. The aim of AS is to monitor the PCa and offer active treatment with curative 
intent to those whose cancer progresses, thereby minimising over-treatment.  
Curative approaches available  include  radical prostatectomy (RP), external beam 
radiotherapy (EBRT) and brachytherapy (32). Watchful waiting (WW) followed by 
ADT for symptomatic control is another option in those not suitable for more 
aggressive curative treatments. In patients with high risk or locally advanced 
disease, options include EBRT with adjuvant ADT or RP with the addition of pelvic 
lymphadenopathy (32).  
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Management of advanced/metastatic disease  
The gold standard management of advanced/metastatic disease has been 
continuous ADT. However, recently, data from several large RCTs, including the 
STAMPEDE trial (33), has shown that the addition of docetaxel chemotherapy to 
ADT at presentation improves overall survival (OS). This is now the recommended 
treatment combination in men with hormone sensitive metastatic disease who are fit 
enough to receive both ADT and chemotherapy (32). 
Management of castrate resistant metastatic disease  
When a patient with metastatic disease has evidence of disease progression whilst 
on ADT, with castrate levels of testosterone, they are said to have developed 
castration resistance. In the last decade several new therapeutic options for this 
group of patients have emerged. Abiraterone acetate is a steroidal 
CYP17A1inhibitor which results in the inhibition of androgen synthesis. 
Enzalutamide is a second generation non-steroidal anti-androgen. The COU-302 
trial tested Abiraterone vs. placebo plus prednisolone and reported improved OS 
(HR: 0.79, 95% CI: 0.66-0.95)(34). The PREVAIL trial tested Enzalutamide vs. 
placebo and also reported improved OS (HR: 0.71. 95%CI: 0.60-0.84) (35). Both of 
these second generation hormonal therapies are approved for treatment of castrate 
resistant metastatic prostate cancer (CRPC) in both the pre and post chemotherapy 
setting.  Docetaxel chemotherapy has also shown improved OS and is another 
option in patients who are fit enough and have not received it in the hormone 
sensitive setting (36). Cabazitaxel is also licensed for use in this setting (37).  
Radium 223 a bone targeted alpha-emitter and Sipuleucel-T, an immunotherapy 
using activated autologous dendritic cells, are also approved for use, though are 








Table 2: Risk groups for PCa from the National Comprehensive Cancer Network 
Guideline(39)  
 Low  risk 
 
Local clinical stage T1-2, 
Gleason score of 2-6 and 
PSA< 10 ng/ml 
 
Intermediate risk T1-2, Gleason score 7 and/or 
PSA 10-20 ng/ml 
High risk T3 and/or Gleason score 8-







T4 and/or N1 and/or PSA 50-
100 ng/ml in the absence of 
distant metastases (M0 or 
MX) 
 




Type 2 Diabetes Mellitus - biology  
Several organs including the pancreas, liver, intestine and kidneys are involved in 
normal glucose homeostasis (Figure 7). T2DM is a metabolic disorder in which 
there is hyperglycaemia, insulin resistance and relative impairment of insulin 
secretion.  Different individuals have varying degrees of insulin resistance and 
insulin deficiency, with both contributing to the onset of hyperglycaemia and T2DM. 
Hyperglycaemia itself impairs the function of pancreatic beta cells which produce 
insulin and leads to a worsening of insulin resistance, in a vicious cycle of metabolic 
impairment (40). 
Several longitudinal studies have examined insulin resistance and insulin secretion 
in the years prior to a diagnosis of T2DM. The Whitehall study followed 6,500 non-
diabetic civil servants for a median follow up of 9.5 years, during which 505 were 
diagnosed with T2DM.  There was a marked decrease in insulin sensitivity in the 
five years prior to diagnosis in those who developed T2DM and this was 
accompanied by an increase in insulin secretion by pancreatic beta cells, in an 
attempt to compensate for the increasing insulin resistance (41).  This process of 
increasing insulin resistance and secretion results in a period of impaired glucose 
tolerance, referred to as the pre-diabetic phase, before overt hyperglycaemia 
develops (Figure 8).   Insulin resistance is in part due to substances secreted from 
adipose tissue including leptin, adiponectin and tumour necrosis factor alpha (42). 
The prevalence of T2DM hence rises markedly with increasing obesity and 





Figure 7: Organs involved in maintaining plasma glucose (44) 
 
 




Type 2 Diabetes Mellitus Descriptive - Epidemiology  
Worldwide 
The number of people with diabetes has risen from 108 million in 1980 to 422 
million in 2014. In the same time period the global prevalence among adults has 
risen from 4.7% to 8.5%.  This dramatic increase is due to a rise in the number of 
cases of T2DM, rather than any change in prevalence of type 1 diabetes (45). The 
International Diabetes Federation (IDF) estimated that in 2015 seven countries had 
more than 10 million people with diabetes: China, India, the United States of 
America; Brazil, the Russian Federation, Mexico and Indonesia (46). Globally, 65% 
of cases are in urban areas and 35% in rural areas (46).  Worldwide in 2015 it has 
been estimated that T2DM caused 1.6 million deaths (47).  It is projected that by 
2030 diabetes will be the 7th cause of death worldwide (45). It is also estimated that 
1 in 2 people globally with T2DM remain undiagnosed (46).  
United Kingdom 
The prevalence of diabetes in the UK matches the global trend and is increasing.  
Since 1996, the number of people diagnosed with diabetes in the UK has more than 
doubled from 1.4 million to almost 3.5 million (48).  Current estimates suggest that 
4.5 million people are living with diabetes, with potentially 1.1 million people 
unaware of their diagnosis. In the UK, T2DM accounts for > 90% of cases of 
diabetes. The national diabetes audit in 2012 suggested that people with T2DM 
were 34.5 % more likely to die than those without T2DM, with a Standardised 
mortality rate (SMR) of 1.34.  It is thought that diabetes accounts for 1% of total 
deaths in the UK (47, 49). 
Sweden and the rest of Europe 
Similar trends of rising prevalence are seen across Europe. The IDF estimates that 
in 2015 660 million people within Europe had diabetes and suggest that by 2040 
this number will rise to 663 million. Prevalence rates vary widely across the region, 
with the highest rates seen in Turkey. In 2015 it was estimated that diabetes 
caused 627,000 deaths across Europe, with slightly more deaths in women 
compared to men (315,000 vs 312,000,respectively) (46).  In Sweden, prevalence 
increased from 5.8 to 6.8% between 2007 and 2013; from 6.6 to 7.9% in men and 
from 5.1 to 5.8% in women. The highest rise was in people older than 65 years but 
was seen across all age categories (Table 3). It has been estimated that the 
prevalence of diabetes will rise in Sweden from 6.8% (2013) to 10.4% by the year 
2050, with 940,000 affected inhabitants (50).  As elsewhere, mortality rates are 
higher in those with T2DM than without. However, in Sweden mortality rates in 
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those with T2DM are falling faster than the general population due to health care 
provision (50).  
 




Type 2 Diabetes Mellitus - Risk factors 
As with PCa, there are several known risk factors for the development of T2DM, 
some of which are non-modifiable, such as age and inherited genetic pre-
disposition and others such as lifestyle factors and obesity which are potentially 
modifiable. The major risk factors are discussed below.  
Age 
As shown above in Table 3, T2DM increases with age, with highest rates seen in 
those over 65 years old. However, with the increasing levels of childhood obesity 
across the developed world, prevalence is rising throughout all age categories 
including in children (50).  
Family history and Genetics  
Those with a family history of T2DM are at higher risk of developing the condition. 
The InterAct case-cohort study examined over 13,000 individuals and a family 
history of T2DM was associated with a higher incidence of T2DM (HR: 2.72, 95% 
CI: 2.48-2.99). This association was only modestly reduced after adjusting for other 
established risk factors such as BMI (HR: 2.44, 95% CI: 2.03 - 2.95).  An even 
higher risk was observed for those in whom both parents had T2DM (HR: 5.14, 
95% CI: 3.74-7.07) (51).  The genetic susceptibility to T2DM is complex and is likely 
to be polygenic. In one meta-analysis of six GWAS looking for candidate genetic 
loci, six new loci were identified. These included loci involved in pancreatic cell 
development and function, as well as some involved in insulin release and action 
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(52).  However, the contribution of these genetic variants to the overall incidence of 
T2DM is low, with lifestyle and environmental factors playing a more significant role.   
Ethnicity  
T2DM risk is up to six times higher in those of South Asian ethnicity and three times 
higher in those of African descent than in white Caucasians (53). This is believed to 
be due to a combination of environmental and genetic factors. This is the converse 
to what is seen in PCa, where risk is lowest in South Asian populations. Little has 
been studied about how ethnicity may impact on the relationship between the two 
conditions. Polymorphism 17q12 rs4430796 is associated with both T2DM and PCa 
and increases risk of PCa in South Asian men in particular (54),  This suggests 
potentially South Asian men who develop T2DM may not be protected from PCa, 
however, further research to explore this is required. 
Obesity  
It is well established that increasing levels of obesity are associated with an 
increasing risk of T2DM (55, 56).  This is due to the associated changes in the 
metabolic micro environment, which lead to peripheral insulin resistance. The 
pattern of fat distribution is also important, with central obesity seeming to be most 
important. Suggesting that waist circumference may be a more sensitive risk 
estimator than BMI (57).  
Lifestyle Factors including diet  
Physical inactivity and sedentary behaviours have been shown to be associated 
with an increased risk of T2DM, even within the context of a normal BMI (58).  
Smoking has also been suggested to increase the risk of T2DM, though a causal 
link has yet to be fully established. In one meta-analysis of 25 studies, current 
smokers had an increased risk of T2DM compared to non-smokers (RR: 1.4, 95% 
CI: 1.3-1.6) and a dose effect with increasing levels of smoking was also observed 
(59).  There are several potential biological mechanisms to explain this potential 
association including that smoking may impair insulin sensitivity, increase the blood 
glucose concentration and result in increased abdominal fat distribution (60, 61). 
The type of diet consumed has also been shown to have either protective or 
detrimental effects on the risk of T2DM. A diet which is high in red and processed 
meat or high in sugar has been shown to be associated with an increased risk (62, 
63).  Whereas a healthy diet high in fruit, vegetables and olive oil has been 




Type 2 diabetes mellitus - Clinical management and treatment  
Screening  
Screening is recommended as up to 50% of patients with T2DM remain 
undiagnosed. The most recent guidelines from the IDF recommend undertaking a 
screening questionnaire, such as the validated FINDRISC (65) questionnaire,  in 
those with risk factors including: age  >45 , family history of T2DM, obesity and 
increased waist circumference. Those who have a positive screening test should 
then undergo the diagnostic process described below.  In those with a negative 
screening test it should be repeated every 3 years (66).  
Symptoms and diagnosis  
Most patients with T2DM are asymptomatic. Symptoms of hyperglycaemia include 
polyuria and polydipsia, but are rarely seen in those diagnosed with T2DM, which is 
most commonly picked up following screening tests or routine blood glucose 
measurements.  
Most guidelines now recommend the use of the IDF and WHO diagnostic criteria for 
T2DM. This includes a fasting glucose of > 7.0 mmol/L or a random glucose >11.1 
mmol/L or a  glycosylated haemoglobin (HbA1c) > 48 mmol/mol (Table 4) (66). 
Glycaemic control and targets  
The recommended glycaemic target for those with T2DM varies between various 
clinical guidelines, but most suggest that HbA1c <53 mmol/mol is an acceptable 
target. If lower levels can be achieved without excess weight loss and 
hypoglycaemia, then this is preferable (66).  
Education  
The majority of major T2DM management guidelines recommend that patient 
education into their condition should be part of the initial management of T2DM.  
The National institute of clinical excellence (NICE) recommends that all patients be 
referred to a diabetes education programme which is run by accredited diabetes 
educators (67).  
Lifestyle, Dietary and Obesity Management  
It is established that lifestyle changes including increasing physical activity, weight 
loss and dietary improvements can help in the management of T2DM and enable 
patients to reach glycaemic targets. However, the exact role they should play in the 
initial management is not universally agreed upon. The IDF recommend that a 
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period of 3-6 month of intense lifestyle and dietary modification, supported by 
patient education, may be appropriate but stress that prolonged periods of 
hyperglycaemia if these measures are not effective should be avoided. Other 
guidelines recommend that initial pharmacological management is instituted 
immediately at diagnosis  alongside these measures (66).  
Dietary advice to those with T2DM who are overweight or obese is to reduce calorie 
intake by 500-600 calories, aiming for a daily intake of between 800-1200 calories. 
Patients should avoid sugar, sweets and sweetened drinks and aim for a high fibre 
diet.  Other important lifestyle advice includes increasing physical activity, smoking 
cessation and avoiding excess alcohol consumption. Anti-obesity drugs should also 
be considered in patients with T2DM and a BMI >27 and bariatric surgery should be 
considered in those with a BMI > 35 (66).   
Oral Hypoglycaemics  
Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide oral hypoglycaemic 
agent (OHA) and is the recommended first line monotherapy in the treatment of 
T2DM (66, 67). Metformin inhibits gluconeogenesis and reduces circulating levels 
of insulin (68). The dose should be titrated from 500mg to 2000mg daily.   If 
metformin is not tolerated or contraindicated then there is no established best 
second option but guidelines recommend one of: a dipeptidyl peptidase-4 (DPP-4) 
inhibitor, pioglitazone or sulphonylurea (SU).  
DDP-4 inhibitors work by inhibiting Glucagon-like peptide-1 (GLP-1). They exert 
their glucose controlling effects via multiple mechanisms including: enhancement of 
glucose-dependent insulin secretion, slowed gastric emptying and a reduction of 
food intake. GLP-1 agonists also have a similar mechanism of action.  
Pioglitazone is a thiazolidinedione which bind to and activates peroxisome 
proliferator-activated receptors (PPARs). PPAR activation causes insulin 
sensitisation, via a decrease in glucose production and an increase in glucose 
utilisation (69). 
SU stimulates insulin secretion. SU binds to the K-ATP channel in pancreatic beta 
cells which regulate insulin secretion. This binding leads to calcium influx into the 
cells and insulin secretion (70).  
If monotherapy with metformin or its replacement is not achieving adequate 
glycaemic control then an additional therapeutic agent should be added. Various 
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combinations are advised. The various risks and benefits of these different classes 
of OHA are described in detail in Table 5. 
Insulin  
Initial insulin therapy is recommended only when patients have unstable 
symptomatic hyperglycaemia. Basal insulin can then be instituted to gain glycaemic 
control rapidly, before being discontinued in favour of the standard OHAs described 
above (66).  If dual therapy with two OHA has still not gained glycaemic control, 
then most guidelines recommend the addition of insulin therapy (66). 
 
 
Table 4: WHO and IDF Diagnostic Criteria for T2DM  





6.1-6.9 mmol/L ≥7.0 mmol/L 
OR 2 hour glucose 
following ingestion of 
75g glucose load 
7.8-11 mmol/L ≥11.1 mmol/L 
OR random glucose in 








Table 5: Risks and Benefits of different classes of OHA taken from the IDF clinical practice 
recommendations for managing T2DM in primary care (66) 
 
 Metformin Sulphonylurea Pioglitazone 
Hypoglycaemia Neutral Moderate/Severe Neutral 
Weight Slight loss Gain Gain 
CKD1 stages 3A, 
3B 
Reduce dose in 3A 
Contraindicated 3B 
 
Higher risk of 
hypoglycaemia 
Neutral 
CKD2 stages 4,5 Contraindicated Contraindicated Neutral 
GI** side effects Moderate Neutral Neutral 
Other side effects  Benefit Neutral Oedema 
Bone fracture 
Major CV3 events Neutral Neutral  Neutral 
CHF4 Neutral Neutral Increased risk 
 
  
1 CKD Chronic kidney disease   
 2 GI Gastrointestinal  
3 CV Cardiovascular  




Metabolic Syndrome - Biology  
MetS is a cluster of disorders including central obesity, hypertension, impaired 
glycaemia and dyslipidaemia.  There are various definitions including those 
proposed by the World Health Organisation (71), National Cholesterol Education 
Program and Adult Treatment Panel III (72) and the IDF (73). See Table 6 for 
comparison of these definitions. The joint statement of major international 
associations (74) defines everybody with three of the following metabolic risks:  
impaired glycaemia, obesity, dyslipidaemia or hypertension as having MetS. 
MetS is associated with a pro-inflammatory state with raised levels of C-reactive 
protein (CRP) and interleukin (IL)-6, which is a proposed biological mechanism by 
which MetS causes an increase in subsequent cardiovascular disease (CVD) and 
T2DM (75, 76).  Another proposed mechanism is that MetS causes a pro-
thrombotic state, with elevated levels of plasminogen activator inhibitor (PAI)-1(77). 
Metabolic Syndrome - Descriptive epidemiology  
As described above the worldwide prevalence of T2DM and obesity continues to 
increase dramatically.  In a US study, using data from the National Health and 
Nutrition Examination Survey (NHANES), the prevalence of MetS increased by 
more than 35% between the periods1988–1994 to 2007–2012, from 25.3% to 
34.2% (78). Therefore, mirroring the global trends for obesity and T2DM. Though 
statistics are not widely collected on the prevalence of MetS, the IDF estimates that 
20-25% of the worlds adult population may have MetS and that they are twice as 
likely to die from CVD or a stroke than those without the syndrome (73). 
Metabolic Syndrome - Risk factors  
Obesity  
Obesity is an important risk factor for MetS. In data from the large US NHANES 
study, MetS was present in only 4.6% of normal weight men but in 22.4%, and 
59.6% of overweight and obese men, respectively (79).  In a further US study, 
increasing waist circumference was also associated with an increasing risk of MetS 
(age, sex and ethnicity adjusted OR: 1.7, 95% CI: 1.3-2.0 per 11 cm) (80).  This 
highlights the importance of fat distribution in MetS, with central obesity being a 
significant component.  
Ethnicity and Others 
Race also appears to be a risk factor for developing MetS. The NHANES study 
demonstrated increased risk in those of Mexican ethnicity, with lowest rates in 
Black Americans. These differences persisted even after adjusting for age, body 
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mass index (BMI), and socioeconomic status (78). Some other postulated risk 
factors include smoking (79), low income (79) and physical inactivity (81). 
Metabolic Syndrome - Clinical management and treatment 
Primary intervention 
Once identified, MetS should be treated to reduce the risk of T2DM and CVD. 
Primary intervention is with lifestyle changes including:  
1. Moderate calorie restriction (to achieve a 5–10 per cent loss of body weight 
in the first year) 
2. Moderate increase in physical activity 
3. Diet modification to high fibre, low sugar and fat diet (73) 
The primary aim of these lifestyle changes should be weight loss, which has been 
shown to delay or reduce the onset of T2DM in high risk, obese individuals with 
impaired fasting glucose. In the Finnish Diabetes Prevention study, 522 middle 
aged, overweight subjects with impaired glucose tolerance were randomised to 
standard care or an intensive lifestyle intervention group. The intervention included 
dietary counselling and circuit-type resistance training sessions. Those in the 
intervention group had significantly more weight loss after one and three years, as 
well as improved glucose and lipid measurements compared to the standard care 
group  (82).  
Secondary Intervention 
For those patients in whom MetS persists after the institution of lifestyle measures, 
pharmacological intervention is recommended. At present this management is 
aimed at the individual components of the syndrome. This includes anti-
hypertensives to treat established hypertension, though no particular class has 
been shown to be beneficial in MetS. Dyslipidaemia management aiming to lower 
low density lipoproteins (LDL) and triglycerides (TGs) and raise high density 
lipoprotein (HDL) .Statins and fibrates should also be considered if appropriate. 
Finally, the American diabetes prevention programme has shown that metformin 
can reduce the development of T2DM in those with impaired fasting glucose.  3,234 
non diabetic persons with elevated fasting glucose were randomised to placebo, 
metformin (850 mg twice daily), or a lifestyle-modification programme. They 
reported that the lifestyle intervention reduced the incidence of T2DM by 58 % and 
metformin by 31 % as compared with placebo (83). This suggests that metformin 
may be a useful therapeutic option in those who have not been able to make 
lifestyle changes successfully. 
44 
 
Table 6: Comparison of the World Health Organisation (WHO), National Cholesterol Education Program and Adult Treatment Panel III (NCEP 
ATP III) and International Diabetes Federation (IDF) definitions of Metabolic Syndrome. 
 WHO NCEP ATP III IDF 
Definition Impaired Glycaemia/T2DM1 + 2 other 
criteria 
3 of 5 criteria present  Central Obesity + 2 other criteria 
Glycaemia  Impaired glucose regulation or T2DM Fasting glucose  >110 
mg/dL 
Fasting glucose >100-125mg/dL or 
T2DM 
Obesity 
(WC2 / WHR3) 
 WHR: 
Men >0.90 cm 
Women> 0.85 cm 
WC: 
Men >102cm 
 Women > 88cm 
WC with ethnic specific values  
Lipids  
TG / HDL4  
TG > 150mg/dL 
Men HDL < 35mg/dL 
Women HDL <39mg/dL 
>150 mg/dL TG > 150 mg/dL 
Men HDL <40mg/dL 
Women HDL <50 mg/dL 
Or specific treatment for lipid 
abnormality 
Hypertension  >160/90 mmHg >130/>85 mmHg On treatment or BP >130/85 mmHg 
 
 
1 - T2DM- Type 2 Diabetes Mellitus  
2 - WC- Waist circumference 
3 - WHR- Waist Hip ratio 




Chapter III: Prostate Cancer and Type Two Diabetes Mellitus 
 
Introduction 
As described above, PCa remains the commonest cancer in men, affecting one in 
eight men in the UK. There are also 3.2 million people in the UK who have been 
diagnosed with T2DM and it is estimated that this will rise to 5 million by 2025 (2). 
PCa and T2DM thus often occur together in the same individual.  
However, the relationship between them is much more complex than just two 
prevalent co-existent conditions. It is established that T2DM increases the risk of 
cancer-specific death from several solid malignancies, including colorectal and 
breast cancer (84); but conflicting evidence exists in the case of PCa. The impact of 
pre-existing T2DM has also been studied in regards to grade and stage of PCa at 
presentation, with conflicting results (85). Moreover, there is emerging evidence 
that the presence of T2DM and other metabolic abnormalities (dyslipidaemia, 
hypertension, and obesity) are associated with a more rapid progression of PCa 
(86, 87). This relationship is further complicated by the fact that standard treatment 
for advanced PCa, ADT, has been suggested to increase incidence of T2DM (88), 
as well as worsen glycaemic control in those with pre-existing T2DM. 
 
To provide a background on the complex association between PCa and T2DM, this 
chapter is set out to explore the following areas: 
1. Impact of pre-existing T2DM on PCa incidence 
2. Impact of pre-existing T2DM on PCa grade and stage  
3. Impact of pre-existing T2DM on PCa outcomes and mortality   





Impact of pre-existing T2DM on PCa incidence  
It is now well established that T2DM increases risk of some solid malignancies, 
although not all the literature supporting this is robust (89). Some studies suggest 
that people with T2DM are as much as twice as likely to die from cancer than those 
without (84). However, the opposite is seen in PCa, with an inverse association 
reported in several published meta-analyses (89).  
 
Bonovas et al. published the first meta-analysis examining T2DM and risk of PCa in 
2004. They included fourteen studies and concluded that T2DM confers a 
statistically significant 9% decrease in relative risk of developing PCa (90).  This 
was followed in 2006 by a meta-analysis conducted by Kasper et al. which included 
19  studies and reported an inverse relationship of a similar magnitude, RR: 0.84, 
95%CI: 0.76-0.93 (91).  Following this, Bansal et al. published an updated meta-
analysis including 45 studies, involving 8.1 million participants and 132,331 PCa 
cases, which also reports an inverse association with a RR of 0.86 (95% CI 0.80-
0.92) (92). More recently, Gang et al. published a further updated meta-analysis 
reviewing the literature up to and including April 2012. This meta-analysis included 
56 studies and also reported an inverse association,  RR: 0.88 ,95%CI: 0.82-0.93 
(93).  Here, I performed a further systematic review of the literature up until June 
2017.  
Evidence Acquisition 
The systematic review was performed in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (94), with 
search terms, inclusion and exclusion criteria all defined a priori. 
Search Strategy 
A computerised literature search of Pubmed to identify full text and abstracts 
published was performed   with and without MESH terms (diabetes, diabetes 
mellitus, prostate cancer, prostate neoplasm, incidence, risk). All references of the 
selected articles were checked, including hand searches.  
Study Eligibility  
The final articles were chosen based on the following set of inclusion criteria:  
 Examined the association of T2DM with PCa incidence/risk  
 Case control or cohort study  
 English Language  




Studies were excluded if they: 
 Examined the association of T2DM with PCa mortality 
 Examined the association of T2DM treatments (i.e. drugs) and PCa 
incidence  
 Were a review article or meta-analysis  
 
Initially, titles were reviewed to assess whether they met inclusion criteria. If, after 
assessing the abstract, there was any doubt regarding its suitability for inclusion, it 
was kept for more thorough, subsequent assessment. The list of potential articles 
was further shortened by performing detailed evaluations of the methods and 
results of each remaining paper. Figure 9 provides more detailed information 
regarding the exclusion process. The strength of each study was assessed using 
the strengthening the reporting of observational studies in epidemiology (STROBE) 
criteria (95) and is presented in Figure 10. 
Data collection 
The following details were recorded for each study: author, year of publication, 
country where study was undertaken, study design, number of patients, 
population/setting, outcome reported and variables adjusted for in the analysis. 
Evidence synthesis  
The literature search identified a total of 896 studies of which 44 were deemed as 
initially relevant. Using the above inclusions and exclusion criteria, 36 were 
excluded (Figure 9). The reasons for exclusion were: included in previously 
published meta-analysis (22), only T2DM patients included (6), full article not 
available (3), outcome not PCa incidence (2), meta-analysis (1), duplicate data (1), 
genetic variant of T2DM examined only (1) (Figure 9). A total of eight studies were 
included in the systematic review (Table 7). 
 
Of these eight studies, five were cohort studies (96-101) and three were case-
control studies (102, 103). Three studies were from European populations, two from 
the USA, two from Israel and one from Australia.  
 
The studies combined included 2,716,302 subjects. Six reported an inverse 
association between T2DM and PCa incidence (96-100, 103), one reported no 
association (102) and in one a positive association was reported (101). Of the six 
studies reporting an inverse association, they all reported similar measures of 
association in the magnitude of a 20% reduction in risk of PCa in those exposed to 
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T2DM as compared to those without T2DM. The one paper which reports no 
statistically significant association is a case-control study in which cases of T2DM 
were patients enrolled in the Freemantle Diabetes Study (102). It is the smallest of 
the studies included here, with 1,289 cases and 5,156 controls - which may account 
for the non-statistical significance of their findings (sub hazard HR: 0.83, 95%CI: 
0.60-1.14), though the direction and magnitude of the association reported is in line 
with the other studies. The study which reported a positive association is a 
retrospective review of 3,162 consecutive men who underwent a prostate biopsy 
due to either an elevated PSA and/or an abnormal DRE (101). This design is 
different to the others studies included here, which were largely based on the 
general population, not on a selected population attending for a prostate biopsy. 
This heterogeneity in the design may account for the findings of a 26% increased 
odds of a positive biopsy in patients with T2DM, compared to those without (Odds 
ratio (OR): 1.26 95%CI: 1.01-1.55). The biological explanation for this finding is 
discussed further below.  
Discussion 
The biological mechanism underlying the inverse association between T2DM and 
PCa risk is not elucidated.  Firstly, several metabolic alterations occur in people 
with T2DM which may protect from PCa. The Insulin-IGF-1 theory of carcinogenesis 
suggests that prolonged hyperinsulinaemia results in reduced insulin binding 
proteins and therefore increased free IGF-1, which results in cellular changes which 
can lead to carcinogenesis via increased mitosis and decreased apoptosis (104).  
There is both laboratory and epidemiological evidence supporting that raised insulin 
levels are associated with increased PCa risk (105, 106).  Patients with T2DM, 
though initially may have raised insulin levels, over time develop hypoinsulinaemia.  
Hence patients with T2DM who have lower levels of insulin over time would be 
protected in terms of PCa risk (107). Several studies have reported a strengthening 
of the inverse association between T2DM and PCa risk with duration of T2DM (108-
110), which serves to strengthen this hypothesis. Prolonged hypoinsulinaemia may 
also result in a reduction of leptin, a hormone involved in energy homeostasis (111), 
raised levels of which have been associated with PCa risk (112, 113).  However, 
there are no published studies specifically examining this relationship between 
insulin and leptin levels in T2DM and risk of PCa.  
 
Another metabolic change which occurs in T2DM is a reduction in testosterone 
levels which has been shown both in vitro and in vivo (114, 115). PCa is 
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testosterone driven (116), therefore a decrease in testosterone is expected to be 
associated with a decreased risk.  
Genetic factors as well as metabolic changes have also been postulated to be 
involved in the protective effect which T2DM appears to have on PCa risk. The 
TCF2 gene confers a predisposition to T2DM and has also been shown to have a 
potential protective effect in PCa.  Similarly, other studies have identified different 
variants in the JAZF1 gene, one associated withT2DM and another associated with 
PCa (117). 
 
Some cross-sectional studies have shown that men with T2DM have lower PSA 
levels, compared to those without T2DM (118) and the rate of change over time is 
also lower (119).  This could result in less screen detected PCa and at least in part 
account for the difference in risk seen. This is supported both by studies in which 
enrolled participants undergo prostate biopsy, which report increased risk of 
positive biopsies in T2DM (101), and by those which show higher grade PCa 
detected in those with T2DM (85). 
Finally, treatments used for T2DM, including metformin, could be potential 
confounders in the association between T2DM and PCa risk, this is discussed later 
in this chapter. 
Conclusion 
The updated systematic review of the literature examining the association between 
T2DM and PCa risk presented here concurs with the previously published findings 
of several meta-analyses, indicating that T2DM has a protective effect on PCa risk. 




Figure 9: Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
flow diagram of article identification, screening, eligibility and inclusion for systematic 
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Study Design No of patients  Population/Setting Outcome Reported  Adjusted for 
Dankner, R, 
2016, Israel 
Retrospective Cohort 2,186,196 Men aged 21-89 covered by a 
large Health Care Provider  
T2DM inversely associated with 




2015, Europe  
Prospective Cohort  139,131 Men aged 35-70 from general 
population 
T2DM inversely associated with 





Lai, G, 2013, 
USA 
Prospective Cohort  295,276 Men aged 50-71 in 6 US States , 
general population  
T2DM inversely associated with 
PCa HR: 0.74; 95%CI: 0.70-0.78 









within RCT  
11,541 Men aged 36-74 with coronary 
heart disease enrolled in a 
secondary prevention trial  
T2DM inversely associated with 








Nested case control 44,352 Men from PCBaSe Sweden  T2DM inversely associated with 
PCa OR: 0.80; 95%CI: 0.76-0.85  
socioeconomic 
status, marital status, 








Figure 10: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies included in the 
systematic review on impact of T2DM on PCa incidence. 






















Case Control  1289 cases 
5156 controls  
 
Cases from Fremantle Diabetes 
Cohort Study and controls from 
general  population 
No significant association reported 
HR: 0.83; 95%CI: 0.60-1.14 
age, sex , post code 
matched controls  
Attner B, 
2012, Sweden 
Case Control 3,545 cases 
26,654 controls 
Cases from Cancer register 
Southern Sweden , Controls from 
general population 
T2DM inversely associated with 
PCa RR: 0.81; 95%CI: 0.72-0.93  
age, sex , county 
matched controls  
Moses KA, 
2012, USA 
Retrospective cohort  3162 Men referred for a Prostate biopsy 
because of abnormal DRE and/or 
abnormal PSA 
T2DM associated with an 
increased odds of positive biopsy 
OR: 1.26; 95%CI: 1.01-1.55 
age, race, BMI, 
prostate volume, 
family history, PSA, 






1 (a) Indicate the study’s design with a commonly used term 
in the title or the abstract 
☒ ☐ ☒ ☐ ☒ ☒ ☒ ☒ 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Introduction         
Background/ 
rationale 
2 Explain the scientific background and rationale for the 
investigation being reported 
☐ ☒ ☐ ☒ ☒ ☒ ☒ ☒ 
Objectives 3 State specific objectives, including any pre specified 
hypotheses 
☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Methods         
Study design 4 Present key elements of study design early in the paper ☒ ☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. Describe 
methods of follow-up 
☒ ☒ ☒ ☒ n/a n/a n/a ☒ 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
n/a n/a n/a n/a ☒ ☒ ☒ n/a 
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(b) Cohort study—For matched studies, give matching 
criteria and number of exposed and unexposed 
☒ ☒ ☒ ☒ n/a n/a n/a ☒ 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
n/a n/a n/a n/a ☒ ☒ ☒ n/a 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, 
if applicable 
☒ ☒ ☐ ☒ ☒ ☒ ☐ ☒ 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and 
details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
☒ ☒ ☐ ☒ ☒ ☒ ☐ ☒ 
Bias 9 Describe any efforts to address potential sources of bias ☐ ☒ ☒ ☒ ☒ ☒ ☐ ☒ 
Study size 10 Explain how the study size was arrived at ☒ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why 
n/a ☒ n/a ☒ ☒ ☒ n/a ☒ 
Statistical 
methods 
12 (a) Describe all statistical methods, including those used to 
control for confounding 
☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
(b) Describe any methods used to examine subgroups and 
interactions 
☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
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(c) Explain how missing data were addressed ☐ ☒ ☐ ☐ ☐ ☐ ☐ ☒ 
(d) Cohort study—If applicable, explain how loss to follow-
up was addressed 
☐ ☒ ☒ ☐ n/a n/a n/a ☒ 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
n/a n/a n/a n/a ☒ ☒ ☒ n/a 
(e) Describe any sensitivity analyses ☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Results         
Participants 13* (a) Report numbers of individuals at each stage of study—
eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing 
follow-up, and analysed 
☒ ☒ ☐ ☒ ☒ ☐ ☐ ☒ 
(b) Give reasons for non-participation at each stage ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
(c) Consider use of a flow diagram ☒ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on exposures 
and potential confounders 
☒ ☒ ☐ ☒ ☒ ☒ ☐ ☒ 
(b) Indicate number of participants with missing data for 
each variable of interest 
☒ ☒ ☐ ☐ ☐ ☐ ☐ ☒ 
(c) Cohort study—Summarise follow-up time (eg, average 
and total amount) 
☒ ☒ ☐ ☒ n/a n/a n/a n/a 
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Outcome data 15* Cohort study—Report numbers of outcome events or 
summary measures over time 
☒ ☒ ☐ ☒ n/a n/a n/a ☐ 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
n/a n/a n/a n/a ☒ ☒ ☒ n/a 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were 
adjusted for and why they were included 
☐ ☒ ☐ ☐ ☐ ☒ ☒ ☒ 
(b) Report category boundaries when continuous variables 
were categorized 
n/a ☒ n/a ☒ ☒ ☒ n/a ☒ 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Other 
analyses 
17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
☒ ☒ ☒ ☐ ☒ ☒ ☐ ☒ 
Discussion         
Key results 18 Summarise key results with reference to study objectives ☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Limitations 19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
☒ ☐ ☒ ☒ ☒ ☒ ☒ ☒ 
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Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
☒ ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Generalisabili
ty 
21 Discuss the generalisability (external validity) of the study 
results 
☒ ☐ ☐ ☒ ☐ ☒ ☐ ☐ 
Other information         
Funding 22 Give the source of funding and the role of the funders for 
the present study and, if applicable, for the original study on 
which the present article is based 





Impact of pre-existing T2DM on PCa grade and stage  
As discussed in the introduction chapter of this thesis, PCa severity can be 
described in terms of its grade and its clinical or TNM stage. Some studies have 
examined whether pre-existing T2DM is associated with a particular grade or stage 
of disease.  In the systematic review of T2DM and PCa incidence (above) including 
studies published after 2012, of the eight new studies identified, only two presented 
subgroup analysis on stage and/or grade (96, 99) (Table 8). These are discussed 
below but another systematic review was not deemed informative, as one including 
literature up until 2013 has previously been published (85). 
Existing Literature 
In 2013, Xu et al. undertook a meta-analysis of all studies examining the 
association between T2DM and PCa risk including subgroup analysis by different 
grade and stage (85). They included nine studies: five examining stage only, two 
grade only and two which explored both. They reported findings of an inverse 
association between T2DM and PCa for both low and high grade PCa, defined as 
Gleason 2-6 and Gleason 7-10 (RR: 0.74, 95%CI: 0.64-0.86 and 0.78, 95%CI: 
0.67-0.90). They reported a RR of a similar direction and magnitude for localised 
and advanced disease (RR: 0.72, 95%CI: 0.68-0.76 and 0.85, 95%CI: 0.75-0.97). 
This meta-analysis included all studies published up until October 2012.   
Updated Literature review  
Two new studies were identified in the systematic review described above which  
specifically considered stage and grade of PCa.  A nested case-control study by 
Fall et al. included 44,352 men with PCa in Prostate Cancer data Base Sweden 
(PCBaSe) Sweden, which is based on the National Prostate Cancer register of 
Sweden (NPCR) (120). They showed an inverse association between T2DM and 
risk of PCa across all risk groups, low, intermediate and high risk/metastatic (OR: 
0.71, 95%CI: 0.64-0.80; 0.76, 95%CI: 0.69-0.84; 0.86, 95%CI: 0.80-0.93, 
respectively).  Whilst they showed a slightly less clear risk pattern for those with 
high risk and metastatic disease, no significant difference between T2DM and risk 
category of PCa emerged from this study.  
 
Tsilidis et al. included 139,131 men from the European Prospective Investigation 
into Cancer and Nutrition (EPIC)  prospective cohort, 4,531 of whom went on to 
develop PCa. They reported no statistical evidence for an inverse association 
between T2DM and PCa risk groups.  There was no evidence that the association 
differed by stage (p-heterogeneity, 0.19) or grade (p-heterogeneity, 0.48) of the 
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disease, although the numbers were small in some subgroups and the study may 
have been under powered to detect differences. 
 
Conclusion 
The meta-analysis by Xu et al. (85) concluded that the protective effect of T2DM on 
PCa risk is seen across different disease grades and stages – however the number 
of studies available are too small to confirm this finding. The two new studies 
identified in the systematic review of T2DM and PCa incidence presented above 
which considered stage and grade (96, 99) reported similar findings of no significant 
difference between different stages and grades of PCa. However, sample sizes 
remain small and no definitive conclusion can be drawn on the impact of T2DM on 
risk of PCa of different grades and stages. Larger studies are required to address 
this question in detail.  
  
Table 8: Overview of the eight papers included in the systematic review on T2DM and 
PCa incidence, by subgroup analysis including PCa stage and grade. 




Dankner, R, 2016, Israel No No 
Tsilidis K, 2015, Europe Yes Yes 
Lai, G, 2013, USA No No  
Lawrence,YR, 2013, Israel No No  
Fall, 2013, Sweden Yes Yes 
Magliano DJ, 2012, 
Australia  
No  No  
Attner B, 2012, Sweden No No 
Moses KA, 2012, USA No  No 
 
Impact of pre-existing T2DM on Prostate Cancer outcomes and mortality   
Introduction 
In 2008, a systematic review and meta-analysis examining all-cause mortality in 
cancer patients reported worse outcomes in cancer patients who had pre-existing 
diabetes mellitus (DM) (121). However, the magnitude of the association varied 
widely between different types of malignancy. This led to a call for research 
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focusing on individual cancer types. Following this, a body of literature has emerged 
and three published meta-analyses have examined the association between pre-
existing DM and PCa specific and all-cause mortality (122-124).  The most recent of 
which was published in 2016. Much of this literature does not distinguish between 
type 1 and type 2 diabetes; hence in this section DM is referred to, encompassing 
both types, unless otherwise specified.  
Existing Literature 
In 2010, Synder et al. performed a systematic review of the literature (seven 
papers), but was only able to include four studies in a meta-analysis. They could 
only investigate all-cause mortality and reported a pooled HR: 1.57, 95%CI: 1.12-
2.20 for DM versus no DM. They concluded that more rigorous research was 
necessary before firm conclusions could be drawn.   
 
Subsequently, a further meta-analysis by Cai et al. (123) was published in 2015, 
which included 11 cohort studies and looked at outcomes of all-cause mortality, 
PCa specific mortality and non PCa mortality. It reported that DM was positively 
associated with all three outcomes, with pooled HR: 1.50, 95%CI: 1.25-1.79, 1.26, 
95%CI: 1.20-1.33, 1.83, 95%CI: 1.33-2.52, respectively.  They concluded that DM 
was associated with an adverse prognosis in PCa and that clinicians treating 
patients with both conditions should pay more attention to the dual diagnosis and 
even consider more aggressive treatment strategies. 
 
The final and most recent meta-analysis by Lee et al. (124) included 17 cohort 
studies which included 274,677 men. The studies were mainly from the USA (eight) 
and Europe (six), with two from Taiwan and one from Korea. They reported a 29% 
increase in PCa-specific mortality (95%CI: 1.37-2.96), alongside a 37% increase in 
all-cause mortality (95%CI: 1.29-1.45).  They were able to perform a subgroup 
analysis of three cohort studies which considered T2DM separately from type 1 DM. 
This analysis showed a two fold increase in all-cause mortality for those with T2DM 
as compared to those without DM (95%CI:1.37-2.96), and could not exclude a 
positive association with PCa-specific mortality (RR:1.17, 95%CI: 0.96-1.42).   
Evidence Acquisition 
As the meta-analysis by Lee et al was published within the last year, a full 
systematic review of the literature was not deemed valuable. However, I reviewed 
the literature since 2016 searching Pubmed using terms (with and without MESH 
terms): PCa, DM, prognosis and mortality. Only one new paper was identified (125).  
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Evidence synthesis  
The additional study identified by Zaorsky et al. was a retrospective cohort study of 
3,217 men with localised PCa undergoing curative radiotherapy. Patients were 
divided into five groups: 1) No T2DM (n=2,603); 2) T2DM on OHA including 
metformin (n=251); 3) T2DM OHA not including metformin (n=148); 4) T2DM on 
insulin (n=89); 5) T2DM - diet controlled (n=126). They examined several outcomes 
including OS, freedom for biochemical failure and cancer specific survival. They 
showed an increased overall mortality in those on insulin (HR: 2.06, 95%CI: 1.17-
3.63) or with diet controlled T2DM (HR: 2.01, 95%CI: 1.24-3.26), but only an 
increase in PCa- specific mortality for those on insulin (HR: 3.91, 95%CI: 1.22-
11.46). These findings may suggest that OHAs are potentially protective in PCa, the 
relationship between metformin and PCa is discussed in detail later in this chapter. 
Whilst interesting, this study contained relatively small numbers in each treatment 
subgroup making it difficult to interpret the results. It also addressed a slightly 
different research question than the previously discussed meta-analysis focusing in 
more detail on the treatment for T2DM, rather than just the presence of absence of 
T2DM.  
Discussion 
All three meta-analyses showed an increase risk of all-cause mortality for patients 
with DM compared to those without. The magnitude varied from a 37% to 57% 
increased risk. T2DM increases cardiovascular mortality amongst a multitude of 
other consequences; increased all-cause mortality for those with T2DM is expected. 
The evidence for PCa-specific mortality is less clear.  Both meta-analyses that 
examined this reported an increased risk in the order of 25-30%, however when 
only studies which included those with T2DM and not type 1 DM were analysed this 
increased risk was not statistically significant – though sample sizes were small for 
these subgroup analyses. In the age group affected most commonly with PCa, 
T2DM is more prevalent than type 1 DM, and so it is assumed that T2DM is largely 
contributing to the increases in both all-cause and PCa-specific mortality 
demonstrated. 
 
A further limitation of the existing literature is that some studies failed to adjust for 
PCa stage or grade, which is an important which is an important co variate 
associated with PCa mortality (7).  This means that positive associations reported in 
these studies could be due to failure to adjust for other important co variates, rather 
than a true effect of DM.  Duration and severity of DM are also important co variates 
which are often not adjusted for. Bensimon et al. (126)  reported a 23% increased 
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risk of PCa-specific mortality and a 25% increased risk of all-cause mortality in 
those with T2DM. They also examined the effect of duration of T2DM and found a 
peak increase in PCa risk between 2-8 years. They also performed a sensitivity 
analysis whereby they excluded those people who developed T2DM during follow 
up, as this could have diluted the risks seen, however, this made no difference.   A 
further limitation of the existing literature is the lack of any competing risk analysis.  
Conclusion 
The existing literature indicates that T2DM is associated with increased risk of all-
cause and may  also increase PCa-specific mortality. However, limitations in 
studies hitherto preclude reliable estimates of what the real sizes of the 
associations are, especially for PCa-specific mortality.   
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Interplay between T2DM and PCa treatments  
Androgen Deprivation therapy and risk of T2DM  
ADT is widely used in the management of PCa. It is the recommended first line 
treatment in all men with advanced disease, as well as in men with high risk 
disease following radical radiotherapy (127).  Even when PCa progresses to a 
castrate resistant phenotype, it is recommended that treatment with ADT continues, 
alongside the addition of further therapies. Given the prolonged clinical course of 
many men with PCa, they can remain on ADT for many years, making any side 
effects associated with treatment potentially significant. 
Common adverse effects of ADT include fatigue, hot flushes and sexual dysfunction 
(128). ADT also increases the risk of cardiovascular disease (129) (130), reduced 
bone mineral density (131) and several North American cohorts have demonstrated 
an increased risk of DM (88, 132-134).  This led the Food and Drug Administration 
(FDA) in 2010 to require a risk label on all GnRH agonists for increased risk of DM 
and certain cardiovascular diseases (myocardial infarction, sudden cardiac death 
and stroke) (135).   
ADT has been shown to induce a metabolic-like syndrome, in which patients have 
decreased insulin sensitivity and increased body fat (136).  I have previously 
undertaken a meta-analysis, including nine published studies, to quantify the 
association between ADT and MetS (137). The RR of MetS for those on ADT 
compared to PCa men not on ADT was 1.75, 95% CI: 1.27-2.41 and for T2DM 
alone 1.36, 95% CI: 1.17-1.58 (Figure 11).  Here I have performed an up to date 
systematic review of the literature examining the association between T2DM and 
ADT. 
Evidence Acquisition 
The systematic review was performed in accordance with the PRISMA guidelines 
(94) with search terms, inclusion and exclusion criteria all defined a priori. 
Search Strategy 
A computerised literature search of Pubmed to identify full text and abstracts 
published was performed.  The search was done with and without MESH terms 
(androgen, androgens, deprivation, therapy, therapeutics, diabetes, and diabetes 




Study Eligibility  
The final articles were chosen based on the following set of inclusion criteria:  
 Original article 
 Examined the association of ADT with the risk of developing T2DM  
 English language article  
Excluded if: 
 Review or meta-analysis  
 Examined elements of the metabolic syndrome which did not include 
T2DM (i.e. hyperglycaemia only)  
Initially, titles were reviewed to assess whether they met inclusion criteria. If, after 
assessing the abstract, there was any doubt regarding whether it met the relevant 
criteria, it was kept for more thorough, subsequent assessment. The list of potential 
articles was further shortened by performing detailed evaluations of the methods 
and results of each remaining paper. Figure 12 provides more detailed information 
regarding the exclusion process. The strength of each study was assessed using 
the STROBE criteria (95) and is presented in Figure 13. 
Data collection 
The following details were recorded for each study: author, year of publication, 
country where study was undertaken, study design, number of patients, type of 
ADT, outcome reported and variables adjusted for in the analysis. 
Evidence synthesis  
The literature search identified a total of 200 studies of which 10 were deemed as 
initially relevant and a further one study was identified using hand searches.  Using 
the above inclusions and exclusion criteria, four were excluded (Figure 12). The 
reasons for exclusion were: outcomes not T2DM (2) and no control group not on 
ADT (2). Seven studies were included in the systematic review (Table 9).   
All seven studies were cohort studies. Five were from North American cohorts (88, 
132-134, 138), one European (139) and one Asian (140). The studies combined 
include 97,893 men on ADT and 287,312 not on ADT. They all report an increased 
risk of T2DM in those men receiving ADT compared to those men that are not, 
particularly in those receiving GNRH agonists. The magnitude of this risk varies 
from a 16% increase reported by Alibhai et al (132) to 61% (138, 139). The one 
outlier is the study by Teoh et al (140) which reports a much higher increased risk, 
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HR: 3.34 (95% CI: 1.19-9.39). However, this is a much smaller study in comparison 
with just a few hundred patients compared to the other cohorts which include 
several thousand patients. This is reflected in the wide confidence intervals that 
they present and as such should be probably regarded as an over estimate of the 
potential risk. However, this is a much smaller study in comparison with just a few 
hundred patients compared to the other cohorts which include several thousand 
patients. This is reflected in the wide confidence intervals surrounding the HR that 
they present.  
Most of the studies in this systematic review included data only on GnRH agonists 
and orchidectomy or combined all forms of ADT. Only two studies examine anti-
androgens (AA) separately (134, 139) and both report no increased risk with those 
receiving AA alone.  
The impact of the duration for which ADT was received and T2DM risk had been 
examined in two studies (88, 132) but with a relatively short exposure time (25 
months).  My study, presented in Chapter IV, examined in greater detail the impact 
of duration of ADT on risk of T2DM, with exposure times of up to greater than 10 
years (139). It showed that the peak risk of T2DM in men receiving GnRH 
agonists/orchiectomy was within the first three years of exposure (i.e.1-1.5 years 
HR: 1.61, 95%CI: 1.36-1.91), before the risk tailed off with continued exposure.  
Thereby showing that the duration of ADT is also important with regards the risk of 
T2DM.  
Discussion 
There is good concordance between all studies examining the risk of T2DM with 
ADT, with all showing an increased risk. The large North American cohort studies 
which led to the FDA requiring a risk label on all GnRH agonists for increased risk 
of T2DM back in 2010 have since been corroborated by further studies in both 
European (139) and Asian populations (140). Additionally the literature 
demonstrates that both the type and duration of the ADT are important in the risk of 
T2DM and should be considered by physicians prescribing ADT. The biological 
mechanisms behind this increased risk are considered in Chapter IV.  
Conclusion 
The literature consistently reports that ADT increases the risk of T2DM and 











Figure 12: Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
flow diagram of article identification, screening, eligibility and inclusion for systematic 
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qualitative synthesis  
(n = 7) 
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Table 9: Characteristics of the 7 Studies included in the systematic review on ADT and T2DM
Author, Year, 
Country  
Study Design No of patients  ADT Type  Main Findings  Adjusted for  










Increased risk GnRH agonists vs. 
PCa free men HR 1.61 (95%CI: 
1.36 - 1.91) 
 
No increased risk AA HR 0.74 
(95%CI: 0.65 - 0.84).  
CCI, PCa risk category , 
education status 
Tsai HT, 2015, USA Retrospective 
Cohort  
2648 ADT vs. 
9543 No ADT  
GNRH 
agonist +/- AA 
Increased risk with ADT vs. No 
ADT HR 1.61 (95% CI 1.38-1.88) 
Age, race, ethnicity, year of 
diagnosis, cancer sequence, 
health plan  
Teoh JY, 2015, Asia Retrospective 
Cohort  
219 ADT vs. 
169 No ADT  
GNRH 
agonist, Orch 
Increased risk GnRH agonist HR 
3.34 (95% CI 1.19-9.39)  
 
Orchiectomy HR 6.49 (95% CI 
1.48-28.55) vs. No ADT  
Age, T Stage, Gleason score, 
hypertension, dyslipidaemia, 
ischaemic heart disease, stroke, 
follow up time, type of ADT, 
duration of ADT   




14,597 ADT vs. 
37,443 No ADT  
AA, GNRH 
agonists, 
CAB,  Orch 
Increased risk with GnRH agonist 
vs No ADT 1.28 (95% CI 1.19 -
1.38)  
 
No increased risk with AA HR 1.02 
(95% CI 0.72-1.45) 
Age, race, ethnicity, year of 
diagnosis, marital status, 
socioeconomic status, Pca stage 
and grade, primary treatment, 
PSA at diagnosis, co morbidities, 
statin use, finasteride use 




19, 076 ADT 





Increased risk HR 1.16 (95%CI: 
1.11–1.21) 
Income and rurality  
Lage MJ, 2007, USA Retrospective 
Claims cohort 
1231 ADT vs. 
7250 No ADT  
Any ADT  Increased risk with ADT HR 1.36 
(95% CI 1.07-1.74) 
Demographic factors, co morbid 
conditions, prior statin use  




26,570 ADT vs. 
46,626 No ADT 
GNRH 
agonist , Orch 
GnRH agonists HR 1.44 (95% CI 
1.34-1.55) Vs. No ADT 
 
Orch HR 1.34 (95% CI 1.20-1.50) 
Vs. No ADT 
age, race, Hispanic ethnicity, 
marital status, residence, SEER 
region, income and education, 
tumor grade, comorbidity score, 
year of diagnosis, primary 
surgical therapy, prevalent 
coronary heart disease 
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Figure 13:  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies included in the 






















Title and abstract 1 (a) Indicate the study’s design with a commonly used term 
in the title or the abstract 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Introduction        
Background/ 
rationale 
2 Explain the scientific background and rationale for the 
investigation being reported 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Objectives 3 State specific objectives, including any pre specified 
hypotheses 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Methods        
Study design 4 Present key elements of study design early in the paper ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. Describe 
methods of follow-up 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
n/a n/a n/a n/a n/a n/a n/a 
(b) Cohort study—For matched studies, give matching 
criteria and number of exposed and unexposed 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
n/a n/a n/a n/a n/a n/a n/a 
71 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, 
if applicable 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and 
details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Bias 9 Describe any efforts to address potential sources of bias ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Study size 10 Explain how the study size was arrived at ☐ ☒ ☐ ☐ ☐ ☒ ☐ 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why 
n/a n/a n/a ☒ ☒ n/a n/a 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
(b) Describe any methods used to examine subgroups and 
interactions 
☒ ☐ ☒ ☒ ☐ ☒ ☒ 
(c) Explain how missing data were addressed ☐ ☐ ☐ ☒ ☐ ☐ ☐ 
(d) Cohort study—If applicable, explain how loss to follow-
up was addressed 
☐ ☐ ☒ ☐ ☐ ☒ ☐ 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
n/a n/a n/a n/a n/a n/a n/a 
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(e) Describe any sensitivity analyses ☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Results        
Participants 13* (a) Report numbers of individuals at each stage of study—
eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing 
follow-up, and analysed 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
(b) Give reasons for non-participation at each stage ☐ ☐ ☒ ☐ ☐ ☐ ☐ 
(c) Consider use of a flow diagram ☐ ☐ ☒ ☐ ☐ ☒ ☐ 
Descriptive data 14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on exposures 
and potential confounders 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
(b) Indicate number of participants with missing data for 
each variable of interest 
☒ ☐ ☐ ☒ ☐ ☐ ☒ 
(c) Cohort study—Summarise follow-up time (eg, average 
and total amount) 
☒ ☐ ☒ ☒ ☒ ☒ ☒ 
Outcome data 15* Cohort study—Report numbers of outcome events or 
summary measures over time 
☒ ☐ ☐ ☒ ☒ ☒ ☒ 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
n/a n/a n/a n/a n/a n/a n/a 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were 
adjusted for and why they were included 




(b) Report category boundaries when continuous variables 
were categorized 
n/a n/a n/a n/a n/a n/a n/a 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
☒ ☐ ☐ ☒ ☐ ☒ ☒ 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
☒ ☒ ☒ ☒ ☐ ☒ ☒ 
Discussion        
Key results 18 Summarise key results with reference to study objectives ☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Limitations 19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
☒ ☒ ☒ ☒ ☐ ☒ ☐ 
Other information        
Funding 22 Give the source of funding and the role of the funders for 
the present study and, if applicable, for the original study on 
which the present article is based 
☒ ☒ ☒ ☒ ☒ ☒ ☒ 
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Impact of T2DM treatments on PCa: Metformin and PCa 
Introduction  
Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide class of OHA  and 
is commonly used for the treatment of T2DM.  As described in Chapter II, metformin 
inhibits gluconeogenesis and reduces circulating levels of insulin (68).  It is also 
thought to play a role in lowering triglyceride and LDL cholesterol levels (141). In 
addition to its anti-diabetic effect, metformin has also been associated with a 
reduced risk of various cancers including PCa (142-144). The literature has 
reported inconsistent results and several meta-analysis have been undertaken in 
attempt to clarify results (145-148).  These are summarised below.  
Existing Literature: Metformin and PCa risk 
In 2015 Deng et al. (147) reported a decrease in risk of PCa with metformin in a 
meta-analysis which included seven studies (RR: 0.88, 95%CI: 0.78-0.99). 
Conversely in the same year, Wu et al. (145) included six cohort and four case-
control studies in a meta-analyses and reported no association with PCa risk (RR: 
0.92, 95%CI: 0.84-1.02).  However, when only cohort studies were considered, a 
small but statistically significant reduction in risk was reported (RR: 0.92, 95%CI: 
0.87-0.96).  Similarly in a larger meta-analysis by Gandini et al. in 2014 (144) 
metformin treatment and PCa risk did not show any association in 12 studies (SRR: 
1.06, 95%CI: 0.80-1.41), though a small but statistically significant association was 
seen when considering just the six prospective studies (SRR: 0.93, 95%CI: 0.89-
0.97).  
Existing Literature: Metformin and PCa mortality and outcomes  
The meta-analysis by Deng et al. (147) described above also examined how 
metformin exposure was associated with all-cause mortality (three studies) and 
BCR of PCa (four studies). They reported that metformin exposure was not 
associated with either all-cause mortality (RR: 1.07, 95%CI: 0.86-1.32) or BCR (RR: 
0.90, 95%CI: 0.75-1.09). Also in 2015 Raval et al. (148) published a systematic 
review and meta-analysis of the impact of metformin exposure on clinical outcomes 
in PCa.  They also report no association with all-cause mortality and PCa specific 
mortality, but reported a marginal association with reduced risk of BCR in five 
studies (HR: 0.59, 95%CI: 0.67-1.01). In a further meta-analysis by Stopsack et al. 
(146) in 2016, including nine retrospective cohort studies of 9,186 patients, no 
overall association with PCa specific mortality was seen, but metformin exposure 
was associated with improved OS in these studies (HR: 0.88, 95%CI: 0.86-0.90) 





As several full meta-analyses and systematic reviews were published in 2015/2016, 
a full systematic review of the literature was not deemed valuable. However, I 
reviewed the literature since 2015 searching Pubmed using terms (with and without 
MESH terms): metformin, prostate cancer, risk, mortality and outcomes. Two 
additional studies were identified (149, 150). 
Evidence Synthesis   
The two new studies identified are summarised in Table 10. Both were large 
Scandinavian cohort studies. Haggstrom et al (149) reported that men with more 
than one year duration of T2DM had a reduced PCa risk, but that those receiving 
metformin specifically did not (HR: 0.96, 95%CI: 0.77-1.19).  Conversely, the 
Finnish study by Haring et al. (150) reported that men using antidiabetic drugs had 
lowered overall PCa risk (HR: 0.85, 95%CI: 0.79–0.92) and among antidiabetic 
drug users, metformin decreased overall PCa risk (HR: 0.81, 95%CI: 0.69–0.95) in 
a dose-dependent manner.  
Discussion 
Despite many studies examining the impact of metformin on PCa risk and 
outcomes they continue to offer conflicting results. This may be explained by the 
wide heterogeneity in the design and quality of these studies.  Much of the literature 
fails to take into account some important potential sources of bias including 
detection bias, immortal time bias, exposure definition and sufficient baseline 
adjustment.  Many studies do not consider that treatment with metformin changes 
through time.  It is also associated with disease severity, and as T2DM severity may 
be on the causal pathway with PCa risk or mortality, it can be said to be a time 
dependent confounder. Standard statistical methods used in much of the literature 
are not able to estimate potential effects correctly controlling for time –dependent 
confounders  (151).The meta-analyses performed to provide clarity, have also 
provided conflicting results. In their meta-analysis Stopsack et al. (146)  attempted 
to take into account the differing designs and quality of the literature. In their 
primary analysis, they only included studies with a clear risk window and in a 
secondary analysis examined those studies with potential immortal time bias. They 
showed that an otherwise modest association with reduced PCa risk was magnified 
in the studies with potential immortal time bias (HR: 0.52, 95%CI: 0.41-0.65).  This 
highlights the need to take into account the quality of studies when performing 
meta-analysis. Two well designed and well powered Canadian studies by Margel et 
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al. (143, 152) reported that an increased cumulative duration of metformin exposure 
after PCa diagnosis was associated with decreases in both all-cause and PCa-
specific mortality among diabetic men, but was not associated with PCa incidence. 
The biological mechanisms underlying these potential associations are reviewed in 
Chapter VI. 
Conclusion 
The current epidemiological evidence shows neither a conclusive decrease in risk 
of PCa risk or improvement in PCa or all-cause mortality with metformin. Further 





Table 10: Two additional studies identified in systematic review of metformin and PCa risk and outcomes 
 
Author, Year, Country  Study Design No of  
patients  
Main Findings  Adjusted for  
Haring, Finland ,2017 Cohort  78,615 Metformin decreased PCa incidence in a dose dependent manner 
(HR 0.81, 95% CI 0.69–0.95) 
Age, trial arm, 
medications  






Impact of PCa on T2DM control and treatments 
Introduction  
The relationship between PCa and T2DM has been extensively studied with respect 
to the effects of T2DM on PCa risk and progression, as described above. However, 
conversely the impact of a PCa diagnosis on the treatment of T2DM has received 
less attention. In this final section, I will consider the impact of PCa on T2DM 
control and treatments. In particular PCa treatments including ADT and 
corticosteroids given alongside chemotherapy may have an impact on the 
management of pre-existing T2DM.  However, there is little literature in this area. A 
systematic review of the published works on this subject is detailed below.  
Evidence Acquisition  
The systematic review was performed in accordance with the PRISMA guidelines 
(94) with search terms, inclusion and exclusion criteria all defined a priori. 
Search Strategy 
A computerised literature search of Pubmed to identify full text and abstracts 
published was performed.  The search was done with and without MESH terms 
(prostate cancer, diabetes control). All references of the selected articles were 
checked, including hand searches.  
Study Eligibility  
The final articles were chosen based on the following set of inclusion criteria:  
 Original epidemiological study 
 Examined the impact of PCa diagnosis or treatment on T2DM control 
or treatment  
 English language article  
The studies were excluded if: 
 Review or meta-analysis  
Initially, titles were reviewed to assess whether they met inclusion criteria. If, after 
assessing the abstract, there was any doubt regarding whether it met the relevant 
criteria, it was kept for more thorough, subsequent assessment. The list of potential 
articles was further shortened by performing detailed evaluations of the methods 
and results of each remaining paper. Figure 14 provides more detailed information 
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regarding the exclusion process. The strength of each study was assessed using 
the STROBE criteria (95) and is presented in Figure 15. 
Data collection 
The following details were recorded for each study: author, year of publication, 
country where study was undertaken, study design, number of patients, main 
outcome and main findings.  
Evidence Synthesis 
The literature search identified a total of 200 studies of which 30 were initially 
relevant.  Using the above inclusions and exclusion criteria, 27 were excluded 
(Figure 14). The reasons for exclusion were: review or meta-analysis (n=13), 
outcome not T2DM controls or treatment change (n=12), not PCa specific (n=1), 
RCT (n=1). Three studies were eventually included in the systematic review (Table 
11).   
All three studies identified were North American cohort studies (153-155). By far the 
largest of these studies by Keating et al. (153) included 2,237 pairs of propensity 
matched men with PCa and T2DM who did or did not receive ADT. They calculated 
mean HbA1c at baseline for both the ADT and No ADT groups and then examined 
the difference in difference at baseline, one and two years between the groups. 
They reported that HbA1c increased at one year for men treated with ADT to 7.38% 
and decreased among men not treated with ADT to 7.14%, for a difference in 
differences of +0.24 (P=0.008). Results were similar at two years (P=0.03). They 
also performed Cox proportional hazards regression model in the propensity 
matched data to assess if ADT was associated with initiating or adding a new class 
of anti-diabetes drug. They reported an increased risk of initiating an additional anti-
diabetic medication in those men on ADT (HR: 1.20, 95%CI: 1.09-1.32), despite the 
rise in HbA1c seen in those receiving ADT.  
Derweesh et al. (154) also examined glycaemic control in men with pre-existing 
T2DM starting on ADT.  Glycaemic control was defined by comparing mean fasting 
blood glucose (FBG) and HbA1c levels before and after ADT for comparison. 
Subsets were then analysed to determine the percentage of patients with a ≥10% 
rise in mean FBG or mean HbA1c after starting ADT. They reported an increase of 
≥10% in serum HbA1c in 15 patients (19.5%) and an increase of ≥10% in FBG in 
22 patients (28.6%). However, there was no comparison group in this study.  
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The final study identified in this systematic review is a descriptive cohort study of 30 
patients with T2DM and genitourinary cancer, 26 of whom had PCa, who were 
receiving corticosteroids alongside their chemotherapy (155). They examined 
changes in T2DM treatment and hospitalisations due to hyperglycaemia and 
reported that 40% of patients required a change in their T2DM management (n=4) 
and 20% (n=2) required hospitalizations for hyperglycaemia.  
Discussion  
This systematic review has highlighted a gap in the existing literature examining the 
impact of PCa and its treatments on the control and management of pre-existing 
T2DM. The studies published and described above all suggest that PCa treatments, 
including ADT and corticosteroids, do impact the management of pre-existing 
T2DM.  In light of the recent change to use of up front chemotherapy, alongside 
ADT, for patients presenting with metastatic disease at presentation, during which 
steroids are given routinely, this will become increasingly clinically important.  
However, the existing studies are very limited. There is a need for further original 
research into this area. In Chapter IV of this thesis I aimed to explore the impact of 




Figure 14: Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
flow diagram of article identification, screening, eligibility and inclusion for systematic 
review on impact of PCa on T2DM control and treatment
Studies included in 
qualitative synthesis  
(n = 3) 
Records identified through 




























Records excluded  
(n =170)    
Full-text articles 
assessed for eligibility  
(n = 30) 
Full-text articles 
excluded, with reasons  
(n = 27) 
Review or Meta-
analysis (n=13) 
Outcome not T2DM 
control or treatment 
change (n=12) 





Table 11: Characteristics of studies included in the systematic review on impact of PCa on T2DM control and treatments 
Author, Year, 
Country  
Study Design No of patients  Main Outcomes  Main Findings  
Keating, 2014, USA Cohort with 
propensity 
matching  
2237 pairs of 
propensity 
matched men with 
PCa and T2DM 
who were or were 
not treated with 
ADT 
The effect of ADT 
onT2DM control, as 
measured by HbA1c 
levels and the 
intensification of T2DM 
drug therapy. 
HbA1c increased at 1 year for men treated with ADT 
(7.38 from 7.24 p value 0.04) 
 
Receipt of ADT was also associated with an 







Cohort 30 GU Cancer 
patients:  
26 PCa 4Bladder 
Ca 
Change in T2DM 
management or 
hospitalisation due to 




40% required a change in their diabetes management  
(n=4) 
 
 20% (n=2) required hospitalizations 
Derweesh, 
2007,USA 
Cohort 77 patients  To assess worsening 
glycaemic control in 
men with established 
T2DM after starting 
ADT for PCa 
An increase of≥10% in serum HbA1c in 15 patients 
(19.5%)  
 




Figure 15: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies included in the 
systematic review of ADT and T2DM 
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Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
☒ ☒ ☒ 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
☒ ☒ ☒ 
Introduction    
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
☒ ☒ ☒ 
Objectives 3 State specific objectives, including any pre specified hypotheses ☒ ☒ ☒ 
Methods    
Study design 4 Present key elements of study design early in the paper ☒ ☒ ☒ 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
☒ ☒ ☒ 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
☐ ☒ ☒ 
Case-control study—Give the eligibility criteria, and the sources and methods 
of case ascertainment and control selection. Give the rationale for the choice of 
cases and controls 
n/a n/a n/a 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
☐ ☒ ☐ 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
n/a n/a n/a 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 





8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
☐ ☒ ☒ 
Bias 9 Describe any efforts to address potential sources of bias ☐ ☒ ☐ 
Study size 10 Explain how the study size was arrived at ☐ ☒ ☐ 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
n/a n/a n/a 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
☐ ☒ ☒ 
(b) Describe any methods used to examine subgroups and interactions ☐ ☒ ☐ 
(c) Explain how missing data were addressed ☐ ☐ ☐ 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed ☐ ☒ ☐ 
Case-control study—If applicable, explain how matching of cases and controls 
was addressed 
n/a n/a n/a 
(e) Describe any sensitivity analyses ☐ ☒ ☐ 
Results    
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Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analysed 
☒ ☒ ☒ 
(b) Give reasons for non-participation at each stage ☐ ☐ ☐ 
(c) Consider use of a flow diagram ☐ ☐ ☐ 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
☒ ☒ ☒ 
(b) Indicate number of participants with missing data for each variable of 
interest 
☐ ☒ ☐ 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) ☐ ☒ ☒ 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over 
time 
☒ ☒ ☒ 
Case-control study—Report numbers in each exposure category, or summary 
measures of exposure 
n/a n/a n/a 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence interval). Make clear which 
confounders were adjusted for and why they were included 
☐ ☒ ☐ 




(c) If relevant, consider translating estimates of relative risk into absolute risk 
for a meaningful time period 
☐ ☒ ☐ 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
☐ ☒ ☐ 
Discussion    
Key results 18 Summarise key results with reference to study objectives ☒ ☒ ☒ 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
☒ ☒ ☒ 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
☒ ☒ ☒ 
Generalisability 21 Discuss the generalisability (external validity) of the study results ☐ ☒ ☒ 
Other information    
Funding 22 Give the source of funding and the role of the funders for the present study and, 
if applicable, for the original study on which the present article is based 




This chapter begun with a systematic review of the impact of pre-existing T2DM on 
PCa incidence and corroborates previously published findings, indicating that T2DM 
has a protective effect on PCa risk. Several potential biological mechanisms and 
possible biases to explain this inverse association were discussed.  Secondly the 
impact of pre-existing T2DM on stage and grade was explored.  Some studies have 
suggested that the inverse association is seen only in low risk cancers and that 
those with T2DM are actually more likely to have higher grade and stage PCa.  
However, this is not consistent with existing meta-analysis and at present no 
conclusion can be drawn on the impact of T2DM on risk of PCa of different grades 
and stages. The existing literature suggests that T2DM may be associated with 
increased risk of all-cause and PCa-specific mortality, but the existing literature has 
some significant limitations. The relationship between T2DM and PCa is further 
complicated by the interaction between the two conditions and their treatments. In 
this chapter, the relationship between ADT and T2DM was examined and there is 
good concordance between all studies, with all showing an increased risk of T2DM.  
The epidemiological evidence examining the relationship between metformin and 
PCa, however, is less convincing. It shows neither a conclusive decrease in risk of 
PCa risk nor an improvement in PCa or all-cause mortality with metformin 
exposure. Finally, in this chapter I have highlighted a gap in the existing literature 
examining the impact of PCa and its treatments on the control and management of 
pre-existing T2DM. Hence in Chapter IV of this thesis I aimed to explore the impact 
of PCa diagnosis on existing T2DM treatment in more detail using data from 
PCBaSe.   
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Chapter IV: PCBaSe  
 
Introduction  
As highlighted in Chapter III, the interplay between T2DM and PCa is complex. 
Several gaps and weaknesses in the literature were highlighted by the systematic 
reviews. These included:  
 The impact of pre-existing T2DM on PCa outcomes and mortality  
 The impact of a PCa diagnosis on the management and control of 
pre-existing T2DM  
 The impact of type and duration of ADT on the risk of T2DM  
In this chapter, using data from PCBaSe I aimed to further examine these important 
elements of the relationship between PCa and T2DM.  
PCBaSe and other national Swedish registries  
The first regional PCa register was established in the South-East health care region 
of Sweden in January 1987. In the early 1990’s similar registers were established in 
further regions. These separate registers amalgamated to form the National 
Prostate Cancer Register (NPCR) of Sweden in 1996. Law mandates that all newly 
biopsy-confirmed PCa cases have to be registered (156). Firstly, each new case is 
reported to the regional cancer register where data are validated and checked for 
completeness, before being entered into the online IT platform for the NPCR, the 
Information Network for Cancer care (INCA) (157). 
NPCR includes information on date of diagnosis, age at diagnosis, tumour stage 
and differentiation and serum levels of PSA at time of diagnosis. PCa risk 
categories are determined according to a modified version of the National 
Comprehensive Cancer Network Guideline (39):  
 Low risk: local clinical stage T1-2, Gleason score of 2-6 and PSA< 10 ng/ml 
 Intermediate risk: T1-2, Gleason score 7 and/or PSA 10-20 ng/ml 
 High risk: T3 and/or Gleason score 8-10 and/or PSA 20—50 ng/ml 
 Regionally metastatic/locally advanced: T4 and/or N1 and/or PSA 50-100 
ng/ml in the absence of distant metastases (M0 or MX) 
 Distant metastases: M1 and/or PSA > 100 ng/ml 
PCBaSe Sweden 2.0 is based on the NPCR of Sweden, which became fully 
nationwide in 1998 and covers 98% of all newly diagnosed cases of PCa, as 
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compared to the Swedish Cancer Register (Figure 16) (120, 156, 158). Using the 
Swedish personal identity number, five PCa-free men from the general population 
in Sweden were randomly selected within sets of men who matched the index case 
on birth year and county of residence and were included in a PCa-free comparison 
cohort (156). Both men with PCa and those in the comparison cohort were 
subsequently linked to a series of national health care registers and demographic 
databases, to obtain data on comorbidity, socioeconomic status, and cause of 
death (Table 12). The aim was to create a database with extensive longitudinal 
data for a population-based nationwide cohort in men with PCa. Subsequent 
versions including PCBaSe 2.1, 2.2 and 3.0 were created with increasing follow up 
times.  
 
A further database PCBaSetraject was then created to capture information on the 
treatment trajectory of individual patients (120). It focuses specifically on men 
diagnosed with PCa between 1992 and 2012, with complete data on treatment 
trajectory (Figure 17).  It includes all data in PCBaSe 3.0, but has additional 
linkages to allow treatment actually received, rather than just treatment planned, to 
be captured. This includes data from RetroRad, a retrospective data collection/ 
verification from oncology information systems and local databases of radiotherapy 
departments. Data collected/verified included type, total dose and fractionation of 
the radiotherapy received. This was necessary as prior to 2008 very little 
information regarding radiotherapy was captured. 
 
As mentioned above PCBaSe is linked to a series of national health care registers 
and demographic databases, to obtain data on comorbidity, socioeconomic status, 
and cause of death (Table 12). The Swedish Cancer Register begun in 1958. Both 
the clinician and the pathologist/cytologist recording the cancer are responsible for 
reporting the case. The linkage to the personal identity numbers, ensures no 
duplicates are recorded.  A registrable cancer is one which is confirmed 
histologically or cytologically, or when diagnosed by a clinician based on other 
diagnostic tests (159).  The patient register includes diagnostic codes for conditions 
in both the inpatient and outpatient setting (156). The Swedish Cause of Death 
Register has existed since 1953 and uses the tenth version of the International 
Classification of Diseases (ICD-10) to capture cause of death data for all persons 
who were registered in Sweden at time of death, regardless of whether the death 
occurred inside or outside of the country (160). There are also linkages to the 
Registers of Total population and Changes and Immigration and Emigration as well 
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as the Swedish Household Census (Table 12).  The Longitudinal database on 
socioeconomic factors (LISA) is collected by Statistics Sweden and is a 
comprehensive socioeconomic database which is updated annually (161). The 
Prescribed Drug Register began on 1st July 2005 and captures all prescribed across 
Sweden (162). The Swedish National Diabetes Register (NDR) began in 1996 in 
response to the Saint Vincent declaration, which called for tools to provide 
continuous quality assurance in the care of people with T2DM. It covers all Swedish 
patients with type 1 or T2DM over the age of 18 years.  Data collected includes 
baseline demographics, risk factors, medications and complications. Currently, over 
90% of hospitals and clinics record their data via an online portal (www.ndr.nu) 
meaning that the vast majority of patients with T2DM are included. However, 
historically coverage was not as wide ranging, particularly in older patients or those 
with multiple co-morbidities (163).  Due to this in the first and third study presented 
in this chapter the prescribed drug register is used to define diabetes based on drug 
prescribing rather than the NDR.  As a result only those receiving pharmacological 
treatment for T2DM are captured. This potential bias is further explored in the 




Figure 16: The six regions in Sweden registering information on prostate cancer 





Table 12: Registers queried for information on subjects in PCBaSe by linkage to the NPCR 
of Sweden and their comparison cohort. 
Register  Data Content 
Swedish Cancer Register  Notification of cancer diagnosis, site and date. 
Reporting mandated by law from clinician and 
pathology department  
Patient Register  In-patient and Out-patient Registers, with 
diagnostic and surgical codes  
Cause of Death Register  Date and underlying and contributing causes of 
death coded according to ICD-10  
Register of the Total 
Population and Changes  
PIN for all Swedish residents, country of birth, 
marital status  
Registers of Immigration and 
Emigration  
Date of immigration and emigration  
Sweden Household Census  Demographics collected 1960–90 including e.g. 
profession  
Longitudinal database on 
socioeconomic factors 
(LISA)  
Extensive set of socio-economic factors with 
annual update including marital status, 
profession.  
The Prescribed Drug 
Register  
All prescribed and dispensed drugs for all 
Swedish residents since July 2005  
National Diabetes Register  Details on diabetes diagnosis and metabolic 










Association between Type 2 diabetes, curative treatment and survival in men 
with intermediate and high risk localised prostate cancer 
This study has been presented as an oral and poster presentation at EAU London 
2017, where it won best poster in session (Appendix 1).  It was subsequently 
published in the British Journal of Urology International in April 2017 (164) 
(Appendix 1).  
 
Rationale 
As discussed in Chapters II and III, PCa and T2DM are both increasing prevalent 
conditions and as a result often occur concurrently in the same patients. Existing 
literature does not fully explore the impact that a pre-existing diagnosis of T2DM 
has on the treatment received for PCa. It is known that there is an association 
between comorbidities (including T2DM) and life-expectancy in men with localised 
PCa (165-167) and current PCa treatment guidelines recommend that a man 
should have a life expectancy of ten years or more in order for curative treatment to 
be indicated (168).  However, the association between pre-existing T2DM, curative 
treatment and survival in men with localised PCa remains unknown. Hence, I used 
data from PCBaSe Sweden to investigate if a diagnosis of T2DM decreased the 
probability of curative treatment in men with localised PCa and how this was 
associated with PCa-specific and all-cause mortality. 
 
Methods 
Study population and data collection  
All men diagnosed with intermediate or high risk localised PCa (i.e. eligible for 
radical treatment with either RP or EBRT) between 1st January 2006 and 31st 
December 2014 were included in the study.  A six month run in period was used 
following the start of the Prescribed Drug Register on 1st July 2005.  The Regional 
Research Ethics Board at Umeå University approved this study.  
 
The main outcome variable for this study, treatment with RP and RT, was retrieved 
from PCBaSetraject, which represents actual treatment received, not just intended 
primary treatment. Only primary treatment, i.e. first definitive treatment received 
after PCa diagnosis and not subsequent treatments were examined. The main 
exposure variable for this study, T2DM, was defined as receiving two or more 
consecutive prescriptions for an anti-diabetic drug within 6 months. Information on 
filled prescriptions of metformin, SU and insulin was obtained from The Prescribed 
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Drug Register using ATC codes (insulin- ANA, metformin- A10BA/BD, SU- A10BB) 
(169).  Less than 2% of those with T2DM received prescriptions for alternative oral 
hypoglycaemics; in this analysis these were considered in the metformin group.   
Those with Type 1 diabetes receiving insulin prescriptions were not excluded; 
however, these cases were few. There were 40 patients with Type 1 diabetes in the 
intermediate and 22 in the high risk PCa group.  Comorbidities were measured by 
the Charlson Co-morbidity Index (CCI), which assigns weights to a number of 
medical conditions, including diabetes and hypertension based on discharge 
diagnoses in the Patient Register (166).  In this analysis, diabetes was excluded 
from the CCI score.  Each condition was assigned a score of 1, 2, 3 or 6 and the 
final CCI is given as the sum of these scores. Individuals were grouped into CCI 
categories for final scores of 0, 1, 2 or 3+ in accordance with previous publications. 
Information on age at diagnosis, T-stage, Gleason score, PSA at diagnosis, 
proportion of cores with cancer, mode of detection of PCa, education and civil 
status was also used. For men with missing data on Gleason score (0.7%), 
multivariate imputation using chained equations (MICE), also known as imputation, 
was applied using fully conditional specifications (170). The MICE method imputes 
multiple variables sequentially using univariate fully conditional specifications.  
Analysis  
Multivariate logistic regression was used to calculate odds ratios for receiving 
curative treatment in men with and without T2DM (as defined above). The analysis 
was adjusted for age, T stage, Gleason score, proportion of cores with cancer, CCI 
(excluding diabetes), mode of detection, education and civil status. When adjusting 
for PSA linear splines with knots at 3, 10 and 20 were used to reflect clinically 
relevant cut offs. 
 
A further analysis was performed to evaluate how an additional diagnosis of 
hypertension, dyslipidaemia, or CVD as compared to only T2DM affected the 
association between T2DM and curative treatment.  ATC codes were used for the 
following prescriptions from the Prescribed Drug register to assess these additional 
diagnoses: statins (C10), anti-hypertensive (C02) and anti-coagulants (B01). 
 
To evaluate the association of PCa and T2DM with survival, a comparison cohort 
including men with only T2DM from the PCa- free cohort was created.  First, all 
index cases were selected (PCa and T2DM, as registered with a date of diagnosis 
from the NDR).  Controls in the comparison cohort were matched with these index 
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cases on age (+/- 1 year), duration of T2DM and type of T2DM treatment (insulin 
vs. OHA). For each index case, five controls were selected. Overall survival up to 
eight years of follow-up was then calculated for men in the comparison cohort and 
for men with T2DM and PCa who did and did not receive curative treatment. 8-year 
survival probabilities were assessed as data was only available for the period 2006-
2014. Finally, the cumulative incidence of PCa specific and death from other 
causes was calculated in those who did and did not receive curative treatment.  
All data management was performed with SAS version 9.3 (SAS Institute, Cary, 
NC) and all data analysis was conducted with R version 2.13.2 (R Foundation for 
Statistical Computing, Wien, Austria). 
Results 
2,210 men with PCa and T2DM and 23,071 men with PCa only were included in the 
analysis. Of those with T2DM, 916 were treated with insulin and 1,537 with 
metformin (Table 13).  Men with T2DM were older than those without T2DM; only 
6% of men with T2DM were under 60 years, compared to 13% of men with no 
T2DM (Table 13).  Men with T2DM also had higher CCI and were more likely to 
have high risk rather than intermediate risk prostate cancer, in comparison to men 
without T2DM (Table 13). Those with T2DM were also more likely to have a 
Gleason score of greater than 8, a higher proportion of cores with cancer and a 
PSA >20 ng/ml (Table 13).   
 
Men with both T2DM and PCa were less likely to receive curative treatment for PCa 
than those without T2DM (OR: 0.78; 95%CI: 0.69-0.87) (Table 14). Men with T2DM 
treated with insulin were less likely to receive curative treatment (OR: 0.62; 95%CI: 
0.53-0.74) than men on metformin (OR: 0.91; 95%CI: 0.80-1.04) (Table 14).  
 
Men with other comorbidities (based on additional filled prescriptions for drugs for 
hypertension, dyslipidaemia, or CVD) in addition to T2DM had virtually the same 
probability of curative treatment for PCa; T2DM only (OR: 0.78; 95%CI: 0.69-0.88), 
T2DM and dyslipidaemia (OR: 0.79; 95%CI: 0.69-0.90), and T2DM and CVD (OR: 
0.75; 95%CI: 0.60-0.93) (Table 15). 
 
The 8 year OS was lower in PCa-free men with T2DM compared to men with T2DM 
and PCa who received curative treatment. At eight years of follow-up, the survival 
was 73% for men with T2DM and no PCa, 79% for men with T2DM and high risk 
PCa who received curative treatment and 33% for men with T2DM and high risk 
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PCa who did not receive curative treatment (Figure 18). Corresponding numbers 
for intermediate risk PCa were 77%, 86% and 55%. The cumulative incidence of 
PCa death was low in both intermediate and high risk PCa when curative treatment 
was received. In men with intermediate risk PCa who were not curatively treated, 
the cumulative incidence of PCa death remained low at 8 years whilst the 
cumulative incidence of death from other causes was much higher. However, in 
those men with high risk PCa the cumulative incidence of PCa death contributed to 
a much greater proportion of the overall death in those not treated curatively 






Table 13: Patient characteristics by diabetes status and diabetes treatment in Prostate 
Cancer database Sweden (PCBaSe) included in the study Association between Type 2 
diabetes, curative treatment and survival in men with intermediate and high risk 





% Insulin % Metformin  % 
 n= 23071  n= 2210  n= 916  n= 1537  
Age at PCa 
diagnosis 
        
 67.9  70  70.1  69.6  
Age, years         
<60 3016 13.1 134 6.1 55 6.0 94 6.1 
60-64 4593 19.9 312 14.1 117 12.8 235 15.3 
65-69 6184 26.8 611 27.6 266 29.0 451 29.3 
70-74 5277 22.9 603 27.3 246 26.9 422 27.5 
75-80 4001 17.3 550 24.9 232 25.3 335 21.8 
         
Year of PCa 
diagnosis 
        
2006-2008 7843 34.0 672 30.4 276 30.1 441 28.7 
2009-2010 8006 34.7 751 34.0 321 35.0 511 33.2 
2011-2012 7222 31.3 787 35.6 319 34.8 585 38.1 
         
CCI2         
0 18985 82.3 1512 68.4 558 60.9 1116 72.6 
1 2428 10.5 383 17.3 183 20.0 245 15.9 
2 1187 5.1 190 8.6 89 9.7 118 7.7 
 3+ 471 2.0 125 5.7 86 9.4 58 3.8 
         





14503 62.9 1187 53.7 468 51.1 825 53.7 
 High risk 8568 37.1 1023 46.3 448 48.9 712 46.3 
         
Educational 
level 
        
Low 7897 34.2 919 41.6 391 42.7 631 41.1 
Middle 9091 39.4 854 38.6 355 38.8 597 38.8 
High 5933 25.7 417 18.9 164 17.9 295 19.2 
Missing 150 0.7 20 0.9 6 0.7 14 0.9 
         
Civil status          
Not married 7241 31.4 779 35.2 332 36.2 551 35.8 
Married 15830 68.6 1431 64.8 584 63.8 986 64.2 
         
Gleason Score          
GS 2-6 4913 21.3 387 17.5 181 19.8 261 17.0 
GS 7 (3+4) 9471 41.1 802 36.3 301 32.9 561 36.5 
GS 7 (4+3) 4378 19.0 458 20.7 191 20.9 307 20.0 
GS 7 UNS 162 0.7 14 0.6 4 0.4 10 0.7 
GS 8 2627 11.4 334 15.1 143 15.6 238 15.5 
GS 9-10 1520 6.6 215 9.7 96 10.5 160 10.4 




        
0-33% 8767 43.5 779 40.3 321 40.4 531 39.1 
33-66% 7043 35.0 650 33.6 267 33.6 467 34.4 
66-100% 4335 21.5 505 26.1 206 25.9 360 26.5 
         
Serum PSA 
(ng/ml) 
        
Table 14: Patient characteristics by diabetes status and diabetes treatment in Prostate Cancer database Sweden 
(PCBaSe) included in the study Association between Type 2 diabetes, curative treatment and survival in men 





1Type 2 Diabetes 
2Charlson Co-morbidity Index 
3Risk groups according to modification of the National Comprehensive Cancer 
Network Practice Guidelines (39) 
4 Androgen deprivation therapy  
 
  
0-3 418 1.9 52 2.5 23 2.6 32 2.2 
3-10 10112 46.0 909 43.0 336 38.5 661 45.1 
10-20 7605 34.6 706 33.4 313 35.9 478 32.6 
20-50 3837 17.5 446 21.1 201 23.0 295 20.1 
         
Primary 
Treatment  
        
ADT4  3552 15.4 560 25.3 276 30.1 336 21.9 
Radical 
Prostatectomy 
9057 39.3 501 22.7 182 19.9 377 24.5 
Radiotherapy  6343 27.5 687 31.1 257 28.1 524 34.1 
Watchful 
Waiting  
4119 17.9 462 20.9 201 21.9 300 19.5 
Table 15: Patient characteristics by diabetes status and diabetes treatment in Prostate Cancer database 
Sweden (PCBaSe) included in the study Association between Type 2 diabetes, curative treatment and 




Table 16: Odds ratios and 95% confidence intervals of curative treatment by diabetes status in the study Association between Type 2 diabetes, 
curative treatment and survival in men with intermediate and high risk localised prostate cancer 
 
 
Crude model is followed by multivariate models with increasing number of factors included as adjustment 
 
1Calculated excluding diabetes  
2For PSA linear splines with knots at 3, 10 and 20 were used 
 
  








Model       
 OR 95%CI OR 95%CI OR 95%CI 
Diabetes 0.58 ( 0.53 - 0.63 ) 0.47 ( 0.41 - 0.53 ) 0.73 ( 0.66 - 0.81 ) 
+ Age  0.73 ( 0.66 - 0.81 ) 0.55 ( 0.47 - 0.65 ) 0.87 ( 0.77 - 0.99 ) 
 +CCI1 0.78 ( 0.70 - 0.86 ) 0.62 ( 0.53 - 0.72 ) 0.91 ( 0.81 - 1.03 ) 
 +T Stage 0.79 ( 0.71 - 0.88 ) 0.62 ( 0.53 - 0.73 ) 0.93 ( 0.82 - 1.05 ) 
 +Gleason 0.75 ( 0.67 - 0.83 ) 0.60 ( 0.51 - 0.71 ) 0.88 ( 0.77 - 0.99 ) 
+PSA2 0.75 ( 0.67 - 0.83 ) 0.61 ( 0.51 - 0.71 ) 0.88 ( 0.77 - 1.00 ) 
+% positive 
cores 
0.74 ( 0.66 - 0.83 ) 0.59 ( 0.50 - 0.70 ) 0.87 ( 0.77 - 0.99 ) 
+mode of 
detection 
0.76 ( 0.68 - 0.84 ) 0.61 ( 0.51 - 0.72 ) 0.88 ( 0.78 - 1.01 ) 
+Education 0.77 ( 0.69 - 0.86 ) 0.62 ( 0.52 - 0.73 ) 0.90 ( 0.79 - 1.02 ) 
+Civil Status 0.78 ( 0.69 - 0.87 ) 0.62 ( 0.53 - 0.74 ) 0.91 ( 0.80 - 1.04 ) 
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Table 17: Odds ratios and 95% confidence intervals of curative treatment in men with diabetes and additional comorbidities compared to 
those with T2DM only in the study Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high 
risk localised prostate cancer 
 T2DM  and 
hypertension3  





Model OR CI OR CI   
       
Crude 0.54 ( 0.49 - 0.60 ) 0.58 ( 0.52 - 0.65 ) 0.48 ( 0.40 - 0.57 ) 
 Age  0.73 ( 0.65 - 0.81 ) 0.73 ( 0.65 - 0.83 ) 0.66 ( 0.54 - 0.81 ) 
 CCI1 0.79 ( 0.70 - 0.88 ) 0.80 ( 0.71 - 0.91 ) 0.79 ( 0.64 - 0.97 ) 
 T Stage 0.80 ( 0.71 - 0.90 ) 0.81 ( 0.71 - 0.93 ) 0.80 ( 0.65 - 0.98 ) 
 Gleason 0.75 ( 0.67 - 0.85 ) 0.77 ( 0.67 - 0.88 ) 0.75 ( 0.60 - 0.92 ) 
PSA2 0.76 ( 0.68 - 0.85 ) 0.77 ( 0.67 - 0.88 ) 0.75 ( 0.61 - 0.93 ) 
% positive cores 0.75 ( 0.66 - 0.84 ) 0.76 ( 0.66 - 0.87 ) 0.72 ( 0.58 - 0.89 ) 
mode of 
detection 
0.76 ( 0.68 - 0.86 ) 0.77 ( 0.68 - 0.89 ) 0.74 ( 0.59 - 0.92 ) 
Education 0.77 ( 0.68 - 0.87 ) 0.79 ( 0.68 - 0.90 ) 0.75 ( 0.60 - 0.93 ) 
Civil Status 0.78 ( 0.69 - 0.88 ) 0.79 ( 0.69 - 0.90 ) 0.75 ( 0.60 - 0.93 ) 
 
The ORs are taken from a multivariate model including all covariates listed 
 
1Calculated excluding diabetes 
2For PSA linear splines with knots at 3, 10 and 20 were used 





Figure 18: Overall survival for men with type 2 diabetes mellitus according to prostate 
cancer risk category and prostate cancer treatment in the study Association between 
Type 2 diabetes, curative treatment and survival in men with intermediate and high risk 
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Figure 19: Cumulative incidence of prostate cancer death and death from other causes 
according to prostate cancer risk category and prostate cancer treatment in study 
Association between Type 2 diabetes, curative treatment and survival in men with 
intermediate and high risk localised prostate cancer 
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Men with T2DM were less likely to receive curative treatment for localised PCa, 
particularly those receiving insulin. While men with T2DM and high risk PCa who 
did receive curative treatment had substantially higher survival compared to men 
with T2DM and PCa who were conservatively treated, those selected for curative 
treatment were found to be the healthiest patients. 
Comorbidities affect 10-year mortality more than PCa-mortality in men with 
conservatively treated localised PCa (165, 167, 171), which has led to the 
recommendation that men should have a 10 year life expectancy or more  in order 
for a  curative treatment to be indicated (168). However, it is difficult to predict an 
individual’s 10 year life expectancy and none of the existing nomograms, which 
help calculate this, are currently widely used in clinical practice (172).   
The impact of comorbidity and age on treatment and survival of men with PCa has 
been investigated in a Dutch study of over 6,000 men (173). The proportion of men 
aged 60–69 years who underwent RP decreased significantly from 32% of men 
without comorbidity to 17% of men with two or more comorbid conditions. This 
proportion decreased further from 8% to 3% in those aged 70–79 years.  A previous 
study using data from PCBaSe demonstrated that as CCI score increased, men 
were more likely to receive RT than RP (174). Our study findings are in line with 
these observations even after taking into account a wide range of potential 
confounders (age, comorbidities and cancer characteristics). 
However, to interpret our findings, it is important to evaluate life expectancy as 
outlined in the guidelines for PCa treatment (168). The life expectancy of a Swedish 
man at age 65 is 19 years, with similar figures seen across Europe (12). T2DM may 
decrease life expectancy by up to 10 years (48). However, men with PCa and 
T2DM who received curative treatment in our study had a substantially higher OS 
than men with T2DM and PCa who received conservative treatment. The selection 
of the healthiest men and allocation to curative treatment among men with T2DM 
and PCa was indicated by the fact that these men had a better OS than 
corresponding PCa-free men with T2DM (Figure 18). The selection of healthy men 
for curative treatment is also highlighted by the lower 90-day mortality after RP 
compared with the background population in a previous Swedish study (175). 
Williams et al. have also demonstrated this selection bias showing a survival 
advantage in men receiving both RP and RT compared to a PCa free comparison 
cohort (176). This selection is also seen here in PCa mortality (Figure19), which 
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remained low regardless of PCa treatment for intermediate risk disease. The higher 
proportion of death from other causes in men not curatively treated confirms that 
these men have high co-morbidity with ensuing increased risk of death from 
competing causes. However, in men with conservatively treated high risk PCa, 22% 
died of PCa within eight years of diagnosis, suggesting that a larger proportion of 
these men should have received curative treatment. In this study, men with T2DM 
were more likely to receive primary ADT than those without T2DM (25% vs.15%) 
(Table 13). Given the metabolic and cardiovascular side effects of ADT, this is 
another reason to ensure that men with PCa and T2DM are not undertreated with 
respect to curative treatment. 
Strengths of this study are its large size, the population-based design and the 
comparison cohort of PCa-free men with T2DM. Furthermore, it benefits from 
access to data from a number of nationwide population-based high-quality registers 
including the Prescribed Drug Register, the Inpatient Register, the Cause of Death 
Register and the NDR. Limitations include that there was only eight years of follow-
up instead of the conventional 10 year survival curves or estimated life 
expectancies.  A further limitation is that by using drug prescriptions as a proxy for 
T2DM, all cases which were treated by diet alone were not included. However, diet 
controlled T2DM is unlikely to have influenced PCa treatment decisions. We show 
that in fact, it is only those treated with insulin who are less likely to receive curative 
treatment. As discussed above it must be acknowledged that a selection bias of the 
healthiest men to receive curative treatment among men with T2DM and PCa 
exists. This was indicated by the fact that these men had a better OS than 
corresponding PCa-free men with T2DM. There may also be confounding by 
indication which influenced selection for curative treatment, i.e. those with the most 
favourable prognosis may have preferentially been chosen for curative treatment. 
By adjusting for tumour characteristics this has been accounted for as much as 





Men with T2DM were less likely to receive curative treatment for localised PCa.  
Those men with T2DM and high risk prostate cancer who received curative 
treatment had substantially higher survival, compared to men with T2DM and PCa 
who were conservatively treated. Some of the survival differences represent a 
selection bias of the healthiest patients to receive curative treatment. However, in 
men with conservatively treated high risk PCa, 22% died specifically of PCa, 
suggesting that a larger proportion of these men should have received curative 
treatment. Clinicians need to interpret such data carefully and ensure that individual 




Impact of a prostate cancer diagnosis on existing diabetes treatment 
This study has been accepted for an oral presentation at the Annual NCRI 
Conference in Liverpool, November 2017 (Appendix 2). It is also under review for 
publication with Diabetes Care. 
Rationale 
With the rapid emergence of several new treatments for PCa in the last six years 
(32) and survival rates improving, even men with advanced disease may live  for 
many years (177). Hence, the need to understand the complex relationship 
between PCa and T2DM is increasingly important for clinicians treating both 
conditions. The systematic review in Chapter III highlighted a gap in the existing 
literature examining the impact of PCa and its treatments on the control and 
management of pre-existing T2DM. This study further investigates the impact of a 
PCa diagnosis on the pharmacological management of T2DM using data from 
PCBaSe. 
Method 
Study population and data collection  
Using PCBaSe 3.0 this study included all men with a diagnosis of T2DM, without a 
pre-existing PCa diagnosis, taken either from the NDR or those receiving anti-
diabetic medications within the Prescribed Drug Register between 2005 and 2014.  
The Regional Research Ethics Board at Umeå University approved this study. 
 
The main outcome variable in this study was a change in T2DM treatment (i.e. 
change from diet-control to metformin or SU or Insulin). Information on filled 
prescriptions of metformin, SU and insulin were obtained from the Prescribed Drug 
Register using ATC codes (insulin- ANA, metformin- A10BA/BD, sulphonylurea- 
A10BB). The initial T2DM treatment was defined using drug prescriptions for anti-
diabetic drugs entered in a six month run in following the date of registration of 
T2DM in the NDR. If the same drug was used in two consecutive 90 day periods it 
was deemed to be the initial T2DM treatment. Follow-up started after the run-in and 
if no drug prescriptions had been filled during that period, then diet control was 
deemed to be the initial treatment. All men who received insulin as initial treatment 
were excluded from the study, since escalation of insulin doses could not be 




The main exposure variable in this study was a diagnosis of PCa taken from 
PCBaSetraject.  PCa treatments, divided into no ADT, anti-androgens (AA) and 
GnRH agonists, were also examined. Exposure to these treatments was taken from 
the Prescribed Drug Register. If a patient received more than one of these 
treatments, they contributed exposure time to each category for the duration of that 
therapy, i.e. a man could have contributed person time to the no ADT group initially 
and then later to the GnRH agonist or AA exposure group after starting hormonal 
therapy. 
Analysis  
Multivariate cox proportional hazards regression was used to calculate hazard 
ratios and 95% CI for one and two T2DM treatment changes in men who had and 
had not been diagnosed with PCa. Age was used as a timescale and all models 
were adjusted for education status and initial T2DM treatment. A further analysis in 
which the exposure was defined as type of PCa treatment received (as defined 
above) was then performed. An analysis examining the risk of consecutive 
treatment changes in patients whose PCa diagnosis came before and after the first 
treatment change was also performed.  
All data management was performed with SAS version 9.3 (SAS Institute, Cary, 
NC) and all data analysis was conducted with R version 2.13.2 (R Foundation for 
Statistical Computing, Wien, Austria). 
Results 
16,778 men with T2DM were included in the study of which 962 were diagnosed 
with PCa during a median follow up of 2.5 years (Table 16).  9692 men (57%) were 
initially treated with diet control and 6373 (38%) received metformin as their initial 
T2DM treatment (Table 16). All baseline characteristics were similar between those 
who were and were not diagnosed with PCa. Table 17 shows the single treatment 
changes captured and the event numbers for each change for all men. 6,205 
treatment changes were seen, the commonest change was from diet control to 
metformin (3495). 1,191 men had two consecutive treatment changes (Table 18). 
There was no association between PCa diagnosis and risk of a single treatment 
change (HR: 0.99; 95%CI: 0.87-1.13) (Table 19). Neither was there any association 
with the type of PCa treatment received (no ADT HR: 0.97; 95%CI: 0.83-1.14, AA 




PCa diagnosis was associated with an increased risk of receiving two consecutive 
T2DM treatment changes (HR: 1.75; 95%CI: 1.38-2.22) (Table 20). This increase 
was strongest in men on GnRH agonists (HR: 3.08; 95%CI: 2.14-4.40). The 
corresponding HR for men with PCa not on ADT was 1.40 (95%CI: 1.03-1.92) and 
for men on AA was 0.91 (95%CI: 0.29-2.82) (Table 20). The increased risk was 
seen only in those who were diagnosed with PCa after a change of T2DM 
treatment, i.e. who were treated with a drug (HR: 3.59, 95%CI: 2.61-4.93), 
compared to those who were diagnosed with PCa prior to any change in T2DM 




Table 18: Patient characteristics for all patients and divided  by those later diagnosed 
with  Prostate Cancer (PCa)  and those who were not  from PCBaSe included in the study 
Impact of a prostate cancer diagnosis on existing diabetes treatment 
 All Men  No PCa  PCa  
 N=16778  N=15816  N=962  
Age onset of 
DM (median) 
 Q1-Q3  Q1-Q3  Q1-Q3 
 71.1 (65.5 - 77.2 ) 71.2 ( 65.6 - 77.3 ) 69 ( 63.1 - 75.5 ) 
Follow Up 
years (median) 
 Q1-Q3  Q1-Q3  Q1-Q3 
 2.5 (1.1-4.3) 2.5 (1.1-4.3) 3.2 (1.5-5.2) 
      
Initial DM 
treatment 
%  %  % 
Diet 9692 57.8 9126 57.7 566 58.8 
Metformin 6373 38 6020 38.1 353 36.7 
Metformin+SU1 79 0.5 75 0.5 4 0.4 
SU1 634 3.8 595 3.8 39 4.1 
       
HBA1c at DM 
Onset (%) 
Q1-Q3  Q1-Q3  Q1-Q3 
 48 43 - 56 48 43 - 56 48 43 - 55 
Missing Hba1c 
(N) 
 %  %  % 
 2310 13.8 2208 14 102 10.6 
       
BMI2 Median 
(kg/m2) 
 Q1-Q3  Q1-Q3  Q1-Q3 
 28.7 26 - 31.6 28.6 26 - 31.6 28.7 26.2 - 31.4 
Missing BMI2  
(N) 
 %  %  % 
 4540 27.1 4305 27.2 235 24.4 
       
Education 
Status 
 %  %  % 
Low 7402 44.1 6998 44.2 404 42 
Middle 6336 37.8 5976 37.8 360 37.4 
High 2810 16.7 2623 16.6 187 19.4 
Missing 230 1.4 219 1.4 11 1.1 
       
Civil Status  %  %  % 
Not married 5649 33.7 5317 33.6 332 34.5 
Married 11129 66.3 10499 66.4 630 65.5 
1SU = Sulphonylurea  2BMI = Body Mass Index 
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Table 19: Single Treatment changes and event numbers in study Impact of a prostate 







SU = Sulphonylurea  
Table 20: Two consecutive treatment changes and event numbers in study Impact of a 
prostate cancer diagnosis on diabetes treatment  
Two Treatment Changes  Event Numbers 
No changes                                                                10573 
One Change 1320 
SU -> Metformin -> Insulin                                                      66 
SU -> Metformin + SU -> 
Insulin                                              
8 
Diet -> Metformin -> Insulin                                                    314 
Diet -> Metformin -> SU                                                    450 
Diet -> SU -> Insulin                                                       60 
Diet -> SU -> Metformin                                               96 
Metformin -> SU -> 
Insulin                                                      
197 
SU = Sulphonylurea  
  
One Treatment  Change                            Event Number 
No Change                            10,573 
Diet -> Metformin                    3495 
Diet -> SU                                       389 
Metformin -> Insulin 695 
Metformin -> SU                                     770 
Metformin + SU -> Insulin                 79 
SU -> Insulin                         129 
SU -> Metformin                                212 
Diet -> Metformin +SU                          19 




Table 21: Hazard Ratios and 95% confidence intervals (CI) for a single change of type 2 
diabetes mellitus (T2DM) treatment by Prostate Cancer (PCa) diagnosis and PCa 
treatments in study Impact of a prostate cancer diagnosis on existing diabetes treatment 
 Multivariate Analysis1 
PCa diagnosis  No PCa 1 REF 
 PCa 0.99 0.87-1.13 
  
  PCa treatment  No PCa 1 REF 
 No ADT2 0.97 0.83-1.14 
 AA3 0.80 0.48-1.36 
 GnRH4 1.12 0.86-1.47 
1Multivariate analysis with age as timescale and adjusted for education status and initial 
diabetes treatment  
2ADT – Androgen Deprivation Therapy  
3AA – Anti androgen 




Table 22: Hazard Ratios and 95% confidence intervals (CI) for two consecutive changes of 
type 2 diabetes mellitus (T2DM) treatment by Prostate Cancer (PCa) diagnosis and PCa 
treatments in study Impact of a prostate cancer diagnosis on existing diabetes treatment 
 Multivariate Analysis1 
PCa diagnosis  No PCa 1.00 (Ref) 
 PCa 1.75 1.38-2.22 
    
PCa treatment  No PCa 1.00 (Ref) 
 No ADT2 1.40 1.03-1.92 
 AA3 0.91 0.29-2.82 
 GNRH4 3.08 2.14-4.44 
    
PCa diagnosis in relation to prior change 
in T2DM treatment  
No PCa 
1.00 (Ref) 
 PCa prior to 1 change 1.09 0.78-1.54 
 PCa after 1 change  3.59 2.61-4.93 
1Multivariate analysis with age as timescale and adjusted for education status and initial 
diabetes treatment  
2ADT – Androgen Deprivation Therapy  
3AA – Anti androgen 






In this population-based cohort study, PCa diagnosis was associated with an 
increased risk of two consecutive T2DM treatment escalations. The association was 
strongest in those men treated with GnRH agonists and in men who were receiving 
pharmacological treatment for their T2DM. 
Prior to this study, all studies examining worsening of glycaemic control and T2DM 
treatments following a PCa diagnosis have focused solely on patients receiving 
ADT.  In a small study of 29 patients with advanced PCa and insulin dependent 
T2DM receiving ADT, Haidar et al. showed a worsening in HBA1c and increasing 
insulin requirements (178).  In a similar US study in 77 patients with T2DM and PCa 
receiving ADT, 15 (19.5%) had a >10% increase in HBA1c (154).  However, there 
were no control men in either of these small single institution studies. The largest 
study to date used the Veterans Affairs observational cohort to study 2,237 pairs of 
propensity matched men with PCa and T2DM who were or were not treated with 
GnRH agonists (153). They showed an increase in HBA1c at one and two years 
despite a 20% increased risk of receiving additional T2DM medications in those 
receiving GnRH agonists. Most recently, a case-control study showed no impact of 
PCa diagnosis on mean HbA1c or glucose (179). However, over 70% of patients in 
this study underwent a radical prostatectomy and therefore did not receive ADT. 
These studies are in line with the findings of the current study that a diagnosis of 
PCa worsens glycaemic control in men with pre-existing T2DM when looking at the 
proxy of escalating pharmacological treatment.  Worsening of glycaemic control 
was strongest in men on GnRH agonists compared to other forms of ADT such as 
AA. This mirrors what has previously been seen with the increased risk of T2DM in 
non-diabetics treated with ADT (139), which is presented below.  However, we also 
show an increased risk of two consecutive treatment escalations in those who are 
not receiving any form of ADT. Current literature has focused only on those 
receiving ADT, so this is a new finding. This may suggest that there is a true 
disease effect of PCa on glycaemic control, not just as a result of treatments 
received. 
This study showed no increase in risk of a single treatment change in those 
diagnosed with PCa.   The risk was highest in those who already had one 
escalation of treatment prior to the diagnosis of PCa. As nearly 60% of the study 
population was initially treated with dietary modification, this suggests those who 
are already receiving a pharmacological treatment for T2DM are at highest risk of 
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further escalations following a PCa diagnosis. This is in concordance with previous 
studies. Keating et al. looked specifically at initiation or addition of insulin therapy 
and found a higher rate in men on ADT vs men not on ADT (94.5 men per 1,000 
person-years vs. 81.2), as a marker of intensification of anti-diabetes management 
(153).  
Biologically, this is not unexpected, as it is known that ADT, particularly GnRH 
agonists, leads to an increase in body fat and a decrease in insulin sensitivity. 
These physiological effects have been shown to occur early after treatment 
initiation (180) and although it has not been directly studied it can be hypothesised 
that similar physiological changes would occur in patients with pre-existing diabetes 
leading to a worsening of glycaemic control and the need for escalating 
pharmacological management.  
Strengths of this study are the large population design of PCBaSetraject and the large 
number of men with T2DM included. The design of the study allows for inclusion of 
a large number of men who subsequently developed PCa. The linkage to both the 
NDR and Prescribed Drug Register allowed detailed data on the initial and 
subsequent T2DM treatments to be accessed. Unlike previous studies, here 
detailed data was available on the type of PCa treatment being received and 
enabling examination of GnRH agonists individually, not only in combination with 
other forms of ADT. Weaknesses include the lack of repeated measures of HBA1c, 
so although it was possible to present median HBA1c at T2DM diagnosis there was 
insufficient data available to examine changes following a PCa diagnosis. However, 
using change in T2DM treatments as a proxy of worsening glycaemic control is a 
clinically relevant outcome. Patients who had insulin dependent T2DM at diagnosis 
were excluded from the study, as data to capture change in insulin doses was not 
available. However, it is unusual for a person with newly diagnosed T2DM to 
require insulin as first line treatment. By using a six month run in window, with 
consecutive 90 day periods, to determine initial T2DM treatment,  it was still 
possible to include any patients who needed a one-off period of insulin to rapidly 
achieve glycaemic control at presentation before moving on to different forms of 
maintenance treatment.  Hence, the numbers lost because of this exclusion were 
small. 
Conclusion  
This study has shown that men with T2DM who are diagnosed with PCa, 
particularly those treated with GnRH agonists, are more likely to have two 
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consecutive treatment escalations in T2DM treatment.  This suggests a need for 
closer monitoring of men with both PCa and T2DM, as co-existence of PCa and its 




Association between duration and type of ADT and risk of diabetes in men with 
prostate cancer  
This study was presented as a poster presentation at the Annual NCRI Conference 
in Liverpool 2015 and was subsequently published in the International Journal of 
Cancer in Dec 2016 (139). It was also shortlisted for the Sylvia Lawler Prize and 
presented at the Royal College of Physicians in June 2016 (Appendix 3). 
Rationale 
As discussed in Chapters II and III, ADT is the recommended first line treatment in 
all men with advanced PCa and is also used in conjunction with radiotherapy in 
locally advanced disease as both neoadjuvant and adjuvant therapy. When men 
progress to castration resistance, it is recommended that treatment with ADT 
continues, alongside the addition of further therapies (32). Given the prolonged 
disease trajectory of PCa, men can remain on ADT for many years (181), making 
any long-term effects associated with treatment significant. As presented in Chapter 
III, several North American cohorts have demonstrated an increased risk of 
diabetes (88, 132-134). In 2010 this led the FDA  to add a risk label on GnRH 
agonists for increased risk of T2DM  and certain cardiovascular diseases (heart 
attack, sudden cardiac death and stroke) (135). Using data from PCBaSe, this 
study investigates the risk of T2DM taking into account the impact of different types 
and durations of ADT (GnRH agonists, AA, and orchiectomy) on risk of T2DM.   
Method 
Study population and data collection 
This study used PCBaSe 3.0, as described in detail above. Information on filled 
prescriptions of AA, GnRH agonists, metformin, SU and insulin was obtained from 
the Prescribed Drug Register using ATC codes (insulin- ANA, metformin- 
A10BA/BD sulphonylurea- A10BB GnRH –L02AE AA- L02BB).  The Research 
Ethics Board at Umeå University approved this study. 
Both men who received primary and secondary ADT, i.e. as a second line treatment 
strategy initiated after primary treatment at the time of disease progression were 
included in the study. Primary treatment was recorded in NPCR as well as the 
Prescribed Drug Register, whereas secondary ADT was retrieved from the 
Prescribed Drug Register only (156).  Co-morbidities were measured by the CCI, 




An analysis whereby PCa men on ADT and PCa-free men were followed to identify 
occurrence of T2DM was conducted. The main outcome T2DM was defined as two 
filled prescriptions for insulin, metformin or sulphonylurea with a maximum time 
between the two prescriptions of 180 days. The date of the first filled prescription 
was used as the date of the event. HRs for T2DM were calculated for men with PCa 
versus the comparison cohort with left truncation using a Cox proportional hazards 
model with age as a timescale accounting for CCI, PCa risk category and education 
status. Left truncation was applied because the Prescribed Drug Register started on 
July 1st 2005.  This allowed for a run-in period of six months and men with a filled 
prescription for anti-diabetic drugs during this period were excluded from the 
analysis. Hence, all men with prevalent T2DM on an anti-diabetic drug were 
excluded.  Follow up started on 1st January 2006 and ended at date of death, date 
of emigration, date of T2DM prescription, or 31 December 2013, whichever came 
first.  Men who received AA or GnRH according to NPCR and had a date of 
diagnosis prior to 1st January 2006 and were found to still be receiving them 
according to the Prescribed Drug Register during the “run in period” were 
considered to have been ‘’exposed’’ since the date of diagnosis (120).  All other 
exposure to AA or GNRH was defined as time from first filled prescription. In case 
of cross over, patients were allowed to change groups and were from then onwards 
considered to be exposed to the treatment in their new group. Thereby, these 
persons contributed person/years in each treatment category. 
The association between duration of ADT and risk of T2DM was assessed using 
multivariate Cox proportional hazards models with left truncation in which exposure 
time was divided into the following intervals: 0-6 months, 6-12 months, 12-18 
months, 18-24 months, 24-30 months, 30-36 months, 36-48 months, 48-60 months, 
60-72 months, 72-84 months, 84-120 months, >120 months. Incidence rates per 
1,000/person years for the different exposure groups were then calculated.   
 
Finally, a sensitivity analysis was conducted in which incidence rates of T2DM were 
compared between men with PCa two years prior to initiation of ADT and men two 
years post initiation of ADT. This analysis included men free of T2DM who 
received their first ADT after 1st of August 2008 to ensure that sufficient data was 
available from the Prescribed Drug Register which only start on 1st July 2005.Those 
men in the sensitivity analysis who developed T2DM in the period 0-2 years prior to 




All data management was performed with SAS version 9.3 (SAS Institute, Cary, 
NC) and all data analysis was conducted with R version 2.13.2 (R Foundation for 
Statistical Computing, Wien, Austria). 
Results 
167,205 PCa-free men and 34,031 men with PCa out of whom 21,874 (64%) 
received GnRH agonists, 9,143 (27%) AA and 3,014 (9%) underwent orchiectomy 
were included in the study (Table 21). Results for men who had undergone surgical 
or medical castration were analysed together in the GnRH/Orch group.  
 
There was a five-fold higher occurrence of metastatic disease at date of diagnosis 
among men in the GnRH compared to men on AA (32% vs 6%). Conversely, five 
times as many men on AA had undergone primary curative treatment and 
subsequently received ADT, compared to men on GnRH (31% vs. 6%)(Table 21). 
 
Table 22 shows the number of events and HRs for men receiving a new 
prescription for insulin, SU or metformin on AA or GnRH/Orch over time compared 
to a PCa free cohort. Those in the GnRH/Orch group had an increased risk, up until 
2.5-3 years of exposure, HR 1-1.5 years of ADT 1.61 (95%CI: 1.36- 1.91), 2-2.5 
years of ADT 1.68 (95%CI:1.4-2.02), 2.5-3 years of ADT 1.42 (95%CI: 1.16-1.76)  
which then reduced,  3-4 years of ADT 1.17 (95% CI: 0.98- 1.40) and 7-10 years 
ADT 0.96 (95% CI: 0.77-1.19).  In contrast, those on AA had no increased risk of 
T2DM during any time period compared to PCa-free men, HR during 0-2 years of 
ADT 0.73 (95% CI: 0.61-0.87), 2-4 years: 0.71 (95% CI: 0.56-0.91) and >4 years  
0.80 (95% CI: 0.61-1.05).   
 
In the subgroup of men treated with insulin only (Table 22), there was a persistent 
increase in risk observed during all time periods for men in the GnRH/Orch group, 
peaking at 2.5- 3 years with a HR of 2.32 (95%CI: 1.67-3.21).  In contrast, those on 
AA had no increased risk of T2DM during any time period compared to PCa-free 
men.  Table 22 reports the corresponding results for those receiving either 
metformin or sulphonylurea. Those in the GnRH/Orch group had a significantly 
elevated risk until 2-2.5 years of exposure (HR: 1.65, 95% CI: 1.35-2.02) before a 
reduction in later time periods which became non-statistically significant. Similarly to 
insulin, no increased risk of T2DM was seen in those on AA at any time period.  
The time-dependent results of Table 22 are also illustrated in Figure 20. 
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The incidence of T2DM for those without ADT was 10/1,000 person-years, for men 
on GnRH agonists/orchiectomy 13/1,000 person-years and 8/1,000 person-years 
for men on AA (Table 23).  
The results of the sensitivity analysis comparing the incidence of T2DM in men with 
PCa two years prior and after initiation of ADT are presented in Table 24. A similar 
increase in risk for T2DM was observed. In men treated with AA the incidence of 
T2DM (receiving insulin) was 1.5 vs 1.7/1,000 person-years two years before and 
after ADT. In those treated with GnRH/Orch, the incidence of T2DM (receiving 
insulin) was 2.2 vs 5.0/1,000 person-years, respectively, and for T2DM (receiving 




Table 23: Baseline characteristics of men with prostate cancer ( PCa) on androgen 
deprivation therapy (ADT) and the matched comparison cohort of PCa-free men in 
Prostate Cancer Data Base included in the study Association between duration and type 
of ADT and risk 
 PCa Free 
Cohort 




n (%) 167,205  
34,031 
9,143 21,874 3,014 
Mean Follow 
up time (SD) 
          
 4.2 (2.5) 3.5 (2.4) 3.6 (2.3) 3.5 (2.4) 3.1 (2.4) 
Age           
Mean age  at 
diagnosis (SD) 
74.8 (8.5) 74.4 (8.4) 71.2 (8.0) 75.2 (8.3) 78.4 (7.3) 
<65 23183 (13.9) 4908 (14.4) 2119 (23.2) 2623 (12.0) 166 (5.5) 
65-74 55348 (33.1) 11806 (34.7) 3893 (42.6) 7247 (33.1) 666 (22.1) 
75-84 70809 (42.3) 14136 (41.5) 2829 (30.9) 9655 (44.1) 1652 (54.8) 
85+ 17865 (10.7) 3181 (9.3) 302 (3.3) 2349 (10.7) 530 (17.6) 
Age at start of 
ADT 
          
<65 - - 3592 (10.6) 1189 (13.0) 2254 (10.3) 149 (4.9) 
65-74 - - 10849 (31.9) 3641 (39.8) 6596 (30.2) 612 (20.3) 
75-84 - - 15493 (45.5) 3766 (41.2) 10059 (46.0) 1668 (55.3) 
85+ - - 4097 (12.0) 547 (6.0) 2965 (13.6) 585 (19.4) 
Entry into 
PCBaSe 
cohort/ Year of 
PCa diagnosis 
          
1997-2001 17889 (10.7) 5389 (15.8) 1145 (12.5) 3687 (16.9) 557 (18.5) 
2002-2005 49375 (29.5) 11281 (33.1) 2738 (29.9) 7446 (34.0) 1097 (36.4) 
2006-2009 64085 (38.3) 11567 (34.0) 3438 (37.6) 7161 (32.7) 968 (32.1) 
2010-2012 35856 (21.4) 5794 (17.0) 1822 (19.9) 3580 (16.4) 392 (13.0) 
CCI           
                                     
0 
110713 (66.2) 22328 (65.6) 6271 (68.6) 14143 (64.7) 1914 (63.5) 
                                     
1 
29651 (17.7) 6247 (18.4) 1587 (17.4) 4048 (18.5) 612 (20.3) 
                                    
2 
15948 (9.5) 3309 (9.7) 793 (8.7) 2215 (10.1) 301 (10.0) 
3+ 10893 (6.5) 2147 (6.3) 492 (5.4) 1468 (6.7) 187 (6.2) 
Education 
Status 
          
Low 78732 (47.1) 16239 (47.7) 3559 (38.9) 10898 (49.8) 1782 (59.1) 
Middle 56051 (33.5) 11579 (34.0) 3422 (37.4) 7252 (33.2) 905 (30.0) 
High 29171 (17.4) 5771 (17.0) 2091 (22.9) 3403 (15.6) 277 (9.2) 



















          
No PCa  167205 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
1. Low risk - - 2334 (6.9) 1180 (12.9) 1068 (4.9) 86 (2.9) 
2. Intermediate 
risk 
- - 6021 (17.7) 2819 (30.8) 2929 (13.4) 273 (9.1) 
3. High risk - - 11775 (34.6) 3469 (37.9) 7410 (33.9) 896 (29.7) 
4. Regionally 
metastatic 
- - 4745 (13.9) 962 (10.5) 3354 (15.3) 429 (14.2) 
5. Distant 
metastases 
- - 8850 (26.0) 591 (6.5) 6956 (31.8) 1303 (43.2) 
6. Missing 
data 
- - 306 (0.9) 122 (1.3) 157 (0.7) 27 (0.9) 
Primary 
Treatment 
          
No PCa 167205 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
ADT - - 24815 (72.9) 4113 (45.0) 17972 (82.2) 2730 (90.6) 
Curative 
treatment  
- - 4352 (12.8) 2887 (31.6) 1402 (6.4) 63 (2.1) 
Deferred 
treatment 




*Adjusted for CCI, PCa Stage, and Education level. 
 
Table 24: Hazard ratios for Insulin, sulphonylurea or metformin in men on ADT compared to a comparison cohort of PCa-free men in the study 
Association between duration and type of ADT and risk of diabetes in men with prostate cancer 
 
Insulin/sulphonylurea/metformin 
Insulin Sulphonylurea /metformin 
ADT years of 
exposure  No Events 
Crude 





95% CI No 
Events 
Crude 
HR 95% CI 
Adjusted  








     
          
No ADT 7932 1 Ref. 1 Ref. 1688 1 Ref. 1 Ref. 6320 1 Ref. 1 Ref. 
AA 0-2 126 0.73 ( 0.61 - 0.88 ) 0.73 ( 0.61 - 0.87 ) 27 0.78 ( 0.53 - 1.14 ) 0.76 ( 0.52 - 1.11 ) 100 0.67 ( 0.55 - 0.82 ) 0.68 ( 0.56 - 0.83 ) 
AA 2-4 71 0.7 ( 0.54 - 0.89 ) 0.71 ( 0.56 - 0.91 ) 16 0.82 ( 0.50 - 1.34 ) 0.83 ( 0.51 - 1.36 ) 55 0.69 ( 0.53 - 0.90 ) 0.71 ( 0.54 - 0.92 ) 
AA >4 61 0.76 ( 0.58 - 0.99 ) 0.8 ( 0.61 - 1.05 ) 9 0.54 ( 0.28 - 1.05 ) 0.59 ( 0.30 - 1.13 ) 52 0.84 ( 0.64 - 1.10 ) 0.88 ( 0.67 - 1.16 ) 
 
     
          
GnRH 0 -0.5 157 1.44 ( 1.23 - 1.70 ) 1.41 ( 1.20 - 1.67 ) 36 1.52 ( 1.09 - 2.12 ) 1.31 ( 0.93 - 1.85 ) 124 1.35 ( 1.13 - 1.61 ) 1.38 ( 1.15 - 1.66 ) 
GnRH 0.5 -1  162 1.54 ( 1.31 - 1.80 ) 1.51 ( 1.28 - 1.79 ) 41 1.82 ( 1.33 - 2.47 ) 1.59 ( 1.15 - 2.19 ) 126 1.45 ( 1.21 - 1.73 ) 1.49 ( 1.24 - 1.80 ) 
GnRH 1-1.5 156 1.62 ( 1.38 - 1.91 ) 1.61 ( 1.36 - 1.91 ) 40 1.91 ( 1.40 - 2.62 ) 1.71 ( 1.24 - 2.37 ) 120 1.52 ( 1.27 - 1.82 ) 1.58 ( 1.31 - 1.90 ) 
GNRH 1.5-2 132 1.47 ( 1.23 - 1.76 ) 1.48 ( 1.23 - 1.78 ) 35 1.84 ( 1.32 - 2.57 ) 1.67 ( 1.18 - 2.36 ) 100 1.4 ( 1.15 - 1.71 ) 1.46 ( 1.19 - 1.79 ) 
GnRH 2-2.5 132 1.67 ( 1.40 - 2.00 ) 1.68 ( 1.40 - 2.02 ) 34 1.96 ( 1.40 - 2.76 ) 1.81 ( 1.27 - 2.56 ) 102 1.59 ( 1.30 - 1.93 ) 1.65 ( 1.35 - 2.02 ) 
GnRH 2.5-3 104 1.41 ( 1.15 - 1.73 ) 1.42 ( 1.16 - 1.76 ) 39 2.49 ( 1.81 - 3.42 ) 2.32 ( 1.67 - 3.21 ) 67 1.17 ( 0.92 - 1.49 ) 1.23 ( 0.96 - 1.57 ) 
GnRH 3-4 143 1.15 ( 0.97 - 1.37 ) 1.17 ( 0.98 - 1.40 ) 45 1.66 ( 1.23 - 2.23 ) 1.58 ( 1.16 - 2.14 ) 100 1.03 ( 0.85 - 1.26 ) 1.09 ( 0.89 - 1.33 ) 
GnRH 4-5 127 1.14 ( 0.94 - 1.39 ) 1.19 ( 0.97 - 1.45 ) 50 2.27 ( 1.71 - 3.01 ) 2.22 ( 1.65 - 2.97 ) 78 1.02 ( 0.82 - 1.28 ) 1.09 ( 0.86 - 1.36 ) 
GnRH 5-6 91 1.06 ( 0.84 - 1.33 ) 1.11 ( 0.88 - 1.40 ) 36 2 ( 1.44 - 2.79 ) 2.01 ( 1.43 - 2.82 ) 56 0.93 ( 0.71 - 1.20 ) 1 ( 0.76 - 1.30 ) 
GnRH 6-7 67 0.95 ( 0.72 - 1.24 ) 1.01 ( 0.77 - 1.33 ) 27 1.88 ( 1.28 - 2.74 ) 1.91 ( 1.30 - 2.82 ) 42 0.88 ( 0.65 - 1.20 ) 0.96 ( 0.71 - 1.31 ) 
GnRH 7-10 101 0.87 ( 0.71 - 1.08 ) 0.96 ( 0.77 - 1.19 ) 32 1.2 ( 0.85 - 1.70 ) 1.28 ( 0.89 - 1.83 ) 71 0.85 ( 0.67 - 1.07 ) 0.95 ( 0.74 - 1.20 ) 
GnRH >10 30 0.6 ( 0.40 - 0.92 ) 0.69 ( 0.45 - 1.05 ) 16 1.51 ( 0.92 - 2.48 ) 1.72 ( 1.04 - 2.84 ) 15 0.5 ( 0.30 - 0.83 ) 0.58 ( 0.35 - 0.96 ) 
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Table 25: Incidence of T2DM per 1,000 person-years in PCa-free men and men with PCa on anti-androgens (AA) or GnRH agonists/orchiectomy 
(GnRH/Orch group) according to anti-diabetic drug prescriptions in the study Association between duration and type of ADT and risk of 








  Insulin 
/Sulphonylurea 
/Metformin 
 Insulin  Metformin 
/Sulphonylurea 
 No of 
events 
Incidence rate No of 
events 
Incidence rate No of 
events 
Incidence rate  
No ADT 7274 10.45 1030 1.47 6244 8.97 
AA 239 8.07 33 1.11 206 6.96 
GNRH/Orch 1258 12.98 287 2.96 971 10.01 
 Prior AA 81 13.64 11 1.85 70 11.79 
 No Prior AA 1177 12.93 276 3.03 901 9.90 
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Table 26: Event number and incidence per 1,000/person years of T2DM treated with Metformin/Sulphonylurea or Insulin in men with PCa two 
years before and after ADT initiation in the study Association between duration and type of ADT and risk of diabetes in men with prostate 
cancer   
 Metformin/Sulphonylurea Insulin 
 2 years prior to 
ADT initiation 
2 years after ADT 
initiation 
2 years prior to 
ADT initiation 
2 years after 
 ADT initiation 


















All 394 10.4 301 10.1 73 1.9 113 3.8 
AA 128 9.1 91 8.1 21 1.5 19 1.7 
 AA initial 
treatment 
50 9.2 44 9.5 10 1.8 10 2.2 
 AA deferred 
treatment 
78 9.0 47 7.1 11 1.3 9 1.4 
GNRH 266 11.1 210 11.3 52 2.2 94 5.0 
 GNRH initial 
treatment 




71 11.7 51 11.2 11 1.8 24 5.2 
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Figure 20: Graphical representation of risk of T2DM by time on GnRH agonists, T2DM was defined by anti-diabetic drug prescriptions (a) 
Insulin, (b) Sulphonylurea or Metformin, (c) Insulin, Sulphonylurea or Metformin in the study Association between duration and type of ADT 





























In accordance with previous studies, this large nation-wide population-based cohort 
study showed that men on ADT had an increased risk of T2DM as defined by filled 
prescriptions for an anti-diabetic drug. In addition, the highest risk of T2DM was 
reached at three years after the start of GnRH/Orch. In contrast, men on 
monotherapy anti-androgens had no such increase.  
In the first study on risk of T2DM for men on GnRH agonists, Keating et al. showed 
an increased risk in men aged >66 with loco-regional PCa (HR for GnRH agonists 
versus no ADT: 1.44, 95% CI: 1.34-1.55) (88). However, this study had a relatively 
short duration of exposure, i.e. 1-4, 5-12, 13-24, >25 months. The same authors 
obtained similar results in a further study including men of all ages with loco-
regional PCa (134). They analysed combined androgen blockade and AA 
separately and did not show an increased risk of T2DM. The effect of duration of 
treatment on risk of T2DM was not examined. A similar study was conducted by 
Alibhai et al. in a Canadian cohort of men aged ≥66 years who received at least 6 
months of ADT (132). They also reported an increased risk of T2DM (HR: 1.16, 
95% CI: 1.11-1.21), but did not examine GnRH and AA separately and combined all 
forms of ADT as a single exposure. There was a trend toward increased risk of 
T2DM with longer exposure to ADT (HR for ADT vs. no ADT: 1.09,  95%CI: 0.9-
1.08 >24 months of exposure compared with HR: 0.99, 95%CI: 0.90-1.08 at 6-24 
months). 
The longest duration of follow up in these studies was 25 months (88). No studies 
had looked at different types of ADT and the effect of duration combined. AA use in 
North America is substantially lower than in Europe, so there are little data from 
these cohorts on AA. In this study the risk of T2DM with up to ten years of exposure 
was studied, which is to our knowledge the longest exposure studied to date. The 
highest risk associated with GnRH agonists occurred relatively early and started to 
decline after three years of treatment. For AA no increased risk was observed.  
The observed temporal changes in risk fit with the physiological and metabolic 
changes previously described for GnRH agonist treatment (180). These changes 
included increased fat mass, reduced lean body mass and increased insulin levels, 
which all have been demonstrated to occur within three months of commencing 
ADT (180, 182, 183). Lee et al. measured lean body mass and fat mass in 65 men 
with PCa on GnRH agonists over a 12 month period. Those with longer prior 
exposure to treatment with GnRH agonists had less fat accumulation and less loss 
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of lean body mass over the 12 month period (182). Similarly, GnRH agonists 
decrease sensitivity to insulin within three months of ADT start (184). Thus, the 
adverse metabolic effects of GnRH agonists occur within months of initiation; the 
consequences of these changes (i.e. developing T2DM) do not peak until several 
years later.  The risk then tails off towards null over time. This suggests that those 
men susceptible to the metabolic effects of GNRH agonists develop T2DM in the 
first few years of treatment. 
Strengths of this study are its large size, population-based design of PCBaSe, and 
long duration of exposure to ADT. The use of an age-matched PCa-free 
comparison cohort allowed us to handle PCa heterogeneity. If men with PCa 
receiving radical therapy or men on active surveillance/watchful waiting had been 
used as the comparison group this would have introduced selection bias as these 
men have a different general health status than men with PCa on ADT. However, 
this approach does not allow us to tease out the disease effect. The sensitivity 
analysis comparing incidence rates of T2DM in men with PCa two years prior and 
after initiation of ADT aimed to assess this. The results remained consistent to what 
was seen when using the PCa free comparison cohort, with a higher incidence of 
T2DM in those receiving insulin observed after two years of GnRH treatment  (2.2 
vs 5.0 /1,000 person years) and not in those treated with AA.  
One limitation of this study is that by using new drug prescriptions as a proxy for 
T2DM, T2DM cases treated by diet alone were not included; however, this would be 
similar for men with and without PCa. It would be interesting in future studies to be 
able to include this group of men. By only including two of the potential OHAs used 
for T2DM (metformin and SU) those with T2DM who were on alternative drugs were 
also not included. However, these only accounted for 1.32% of events in this study. 
Another limitation is the lack of information about lifestyle factors including weight or 
family history of T2DM. However, all results were adjusted for CCI, which accounts 
for other comorbidities associated with lifestyle risk factors (185), as well as 
education status – which has also been shown to be a good indicator of baseline 
health status (185). Despite adjusting for several covariates, residual confounding 
may still be present. However, adjustment for CCI and education status reduces 
this possibility substantially. A further limitation is that the different risks observed 
between GnRH agonists and AA could potentially be explained by selection bias, 
rather than a real difference in the two treatments. Men treated with GnRH agonists 
are not only more likely to have locally advanced or distantly metastatic disease, 
they are also more likely to have more comorbidities than those treated with AA. 
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This reflects standard clinical practice whereby GnRH agonists are used as a 
primary treatment for advanced disease. Hence, men on GnRH agonists may be at 
higher risk of T2DM than those on AA; this however, does not diminish the clinical 
importance of identifying those at highest risk of T2DM during ADT.  
 
Conclusion 
The duration of GnRH agonists had a significant impact on risk of T2DM in men 
with PCa, with the peak risk observed after three years of treatment. This suggests 
that even men receiving adjuvant ADT, for a short time period, may be at increased 
risk of T2DM.  
Summary of findings in PCBaSe  
In this chapter I have used data from PCBaSe to further explore the complex and 
multidirectional relationship between T2DM and PCa.  
 
Firstly, I have shown that men with T2DM are less likely to receive curative 
treatment for intermediate or high risk PCa than those without T2DM. Also, in those 
men with high risk PCa who did not receive curative treatment, a substantial 
amount died specifically of PCa, suggesting that a larger proportion of these men 
should potentially have received curative treatment.  Hence, this study showed that 
the concurrent diagnosis of both conditions can impact upon the type of treatment 
received for PCa.  
 
Secondly, I have found that having both conditions impacts upon the treatment 
received for T2DM.  Men with T2DM diagnosed with PCa are at higher risk of two or 
more consecutive treatment changes than those not diagnosed with PCa, 
suggesting a worsening of glycaemic control following a PCa diagnosis.   
 
Finally, the interplay between T2DM and PCa is further complicated by the fact that 
ADT, used as a treatment of PCa, increases the risk of developing T2DM in men 
previously free of T2DM.  Furthermore, this risk was dependent on both the type 
and duration of ADT used, with GnRH agonists leading to an increased risk of 
T2DM which was highest in the first three years of treatment.  
 
Taken together, these studies highlight the need for clinicians treating men with 
both PCa and T2DM to be aware of the impact that one has on the other and that a 
132 
 
multi-disciplinary approach to their care between endocrinologists, urologists and 
oncologists is essential to achieve optimal care for both conditions.  
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Chapter V: Effect of baseline metabolic aberrations in men with 
advanced prostate cancer treated with ADT on disease 
progression, prostate cancer-specific and all cause death 
 
This study was presented as a poster presentation at European Society of Medical 
Oncology (ESMO) Annual conference in 2016 in Copenhagen and was awarded 
the prize for best poster in the genitourinary, prostate session (Appendix 4).  The 
manuscript of the study is currently under review with the International Journal of 
Cancer.  
Rationale  
Some studies have suggested that MetS, or some of its features, are associated 
with high-grade PCa (186, 187) . As discussed in Chapter III and IV, ADT has been 
shown to induce a metabolic–like syndrome (6). It has also been suggested that the 
presence of MetS either at diagnosis or its development after initiation of ADT may 
identify those men who are at risk of more rapid progression through first-line ADT 
(86, 87, 188) . 
However, this hypothesis has never been investigated in a large cohort of patients. 
This study examines the effect of baseline metabolic aberrations (T2DM, 
hypertension, dyslipidaemia and obesity) on outcomes of disease progression, 
PCa-specific and all cause death in a cohort of men with locally 
advanced/metastatic PCa starting ADT. 
Methods 
Study design and population 
The study was conducted using a retrospective review of prospectively-collected 
data of men enrolled in the MRC STAMPEDE trial who were allocated to the control 
arm, A. STAMPEDE is a MRC-sponsored, National Institute for Health Research 
(NIHR) Cancer Research Network (CRN)-supported randomised controlled trial for 
patients with locally advanced or metastatic PCa in the UK and Switzerland (189, 
190). The original randomised controlled trial platform opened to accrual in October 
2005 with six arms (Figure 21). It remains open to recruitment and, to date, has 
recruited >8000 patients across nine randomised comparisons. It is designed to 
examine the benefits of treatment additions to standard care ADT and EBRT as 
relevant. EBRT was mandated for N0 M0 patients from November 2011. At the time 
of the data freeze on 25th September 2015, the control arm cohort analysed here 




Definition of metabolic aberrations 
Data collected within STAMPEDE were assessed to define baseline metabolic 
aberrations at enrolment into the study. Due to the nature of this analysis using trial 
data, where calculating metabolic profile was not the main focus, the full set of 
metabolic baseline data which would fulfil all of the joint statement of major 
international association’s definition of MetS was not available (74). Therefore, 
here, the data were assessed for the presence or absence of the following 
metabolic aberrations at baseline: 
1. Hypertension (systolic blood pressure ≥140mmHg and/or diastolic blood 
pressure ≥90mmHg or confirmed history of hypertension)  
2. Obesity (BMI >30kg/m2)  
3. Dyslipidaemia (HDL <1.9mmol/l) 
4. Impaired Glycaemia (confirmed history of T2DM)  
These criteria were as close to the joint statement of major international 
association’s definition of MetS as possible from the available data. These 
metabolic aberrations were then analysed individually and together (as a composite 
metabolic risk score identifying how many components were present). Those with a 
composite score of three or more are below referred to as having composite 
metabolic aberrations (CMA). 
 
Analysis   
Cox proportional hazards models were used to estimate hazard ratios and 95% 
confidence intervals comparing patients with and without baseline CMA, and 
individual metabolic aberrations, for outcomes of PCa progression and death. PSA, 
local and metastatic progression were defined as per STAMPEDE trial protocol 
(189). 
To define PSA progression, the extent of the primary response has to be taken into 
account. Three groups of patients are defined in the trial:   A. If the PSA nadir is 
more than 50% of the last pre-treatment PSA and the PSA nadir is more than 
4ng/ml, the patient should be defined as a treatment failure (at time zero).  B. For 
patients whose PSA nadir is less than or equal to 50% of the last pre-treatment 
PSA, but remains above 4ng/ml, PSA relapse will be deemed to have occurred 
when PSA is confirmed as increasing by 50% above the nadir level. C. For patients 
whose PSA falls below or to 4ng/ml, PSA relapse will be defined by either 50% 
increase from their nadir or the PSA increasing above 4, whichever is the greater. 
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For example, a nadir PSA of 3.6 would require a PSA of 5.4 to define relapse, while 
PSA nadir of 2.5 will be considered to have relapsed at a PSA of 4. The trial 
protocol states that if the PSA value reaches the progression value, a confirmatory 
PSA test should be performed between one week and 3 months later. Biochemical 
failure is confirmed if the second value is around the same level or higher. In 
patients with measurable baseline disease as per RECIST criteria (191), local and 
metastatic progression are defined as at least a 20% increase in the sum of target 
lesions or the appearance of one or more new lesions.  Progression (local or 
metastatic) for patients with non-measurable disease at randomisation is defined as 
increasing clinical or radiological evidence of disease since study entry.   
These outcomes were combined into an overall PCa progression outcome, but 
were also studied separately. All cause death and PCa-specific death (PCSD) were 
also investigated. It is important to note that the failure free survival (FFS) end point 
as used in the STAMPEDE trial previously (189) was not used in this analysis, to 
allow for consistency with the few pre-existing studies in this area (86, 87, 188).  
Univariate and multivariate analyses were performed. The multivariate analysis was 
adjusted for age, Gleason sum score, PSA pre-ADT, type of long-term ADT and 
TNM stage. Median follow-up was determined through the standard approach of 
reverse-censoring on death, in which survival is treated as the event and death as 
censoring. Competing risk analysis was not performed for the PCSD data as in this 
cohort of men with advanced disease the importance of other competing risks of 
death would be less important than when studying men with earlier stages of PCa 
(192); nor were competing risks used in assessing each type of progression.  A 












A total of 2,622 patients treated with ADT (+/-EBRT) who were randomised to the 
control arm of STAMPEDE between October 2005 and September 2015 were 
included in this analysis. The data were frozen on 25th September 2015. Median 
follow up time in this cohort was 21 months. The patient characteristics are 
summarised in Table 25. Median age at randomisation was 66 years. 2,663 (98%) 
patients received GnRH agonist treatment. In this population, 1,844 (87%) had 
dyslipidaemia, 1,466 (56%) hypertension, 686 (28%) were obese and 220 (9%) had 
T2DM. In the dataset, 1105 (42%) patients had a PCa progression event and 523 
(20%) had died, including 411 from PCa. 
471 patients (18%) fulfilled the criteria for CMA. Of those with CMA, 460 (99%) had 
low HDL, 454 (96%) hypertension, 408 (87%) were obese and 157(33%) had 
T2DM. There were 1,017 PCa progression, 1,005 PSA progression, 192 local 
progression and 501 metastatic progression events. Using Cox proportional 
hazards regression analysis, no evidence of an association was observed between 
baseline CMA and PCa progression (HR: 0.97, 95% CI: 0.82-1.14) or for any of the 
individual metabolic aberrations (Table 26). However, presence of CMA was 
associated with a worsening of time to local progression (HR: 1.61, 95% CI: 1.09-
2.36) (Table 27). No evidence of a difference was observed between any of the 
individual metabolic aberrations and time to local progression, though a trend with 
low HDL levels was observed (HR: 1.65, 95%CI: 0.92-2.98). No difference was 
observed between the individual metabolic aberrations and time to metastatic 
progression, though a trend was noted for those with CMA (HR: 1.23, 95% CI: 0.96-
1.57) (Table 27). No difference was observed in OS or PCSD in those with and 
without baseline metabolic aberrations or CMA (Table 28). A stratified analysis 
according to metastatic status at randomisation was performed (Table 29). A 
worsening of time to local progression in those with CMA was only seen for those 
who already had metastatic disease at randomisation (HR: 1.66, 95%CI: 1.08-2.55). 
However, the p value for the interaction test was p= 0.1102, therefore there was no 




Table 27: Baseline characteristics of men with locally advanced / metastatic PCa treated 




n= 2,622 (SD) 
No CMA1  
n = 2,151 (SD) 
CMA1 
n= 471 (SD) 
Age (years) 
Median (IQR) 67(10) 67(10) 67 (10) 
Range  37-84 39-84 37-84 
    
PSA pre-ADT (ng/L) 
Median (IQR) 62 (154) 62 (175) 56 (115) 
Range  0-20590 0-20590 0-8760 
        
 
Median F/U time 
(months) 
21 20 20 
    
Mean (SD) 
BMI (kg/m2) 28.17 (6.60) 26.94 (6.32) 33.40 (5.06) 
    
SBP (mmHg) 141.50 (18.20) 140.52 (18.18) 145.76 (17.69) 
    
DBP (mmHg) 82.37 (27.66) 82.03 (25.59) 83.81 (35.25) 
    
HDL (mmol/L) 1.52 (2.06) 1.61 (2.32) 1.23 (0.35) 
    
Frequency (%) 
Smokers 323 (13) 293(14) 30(6) 
Non Smokers 2196 (87) 1762 (86) 439 (93) 
Missing  98  98  98 
Staging at randomisation: 
T0 8 (<1) 8 (<1) 0 (0) 
T1 32 (1) 28 (1) 4 (<1) 
T2 214 (8) 160 (7) 54 (11) 
T3 1740 (66) 1435 (67) 305 (65) 
T4 474 (18) 398 ( 18) 76 (16) 
TX 154 (6) 122 (6) 32 (7) 
        
N0 1307 (50) 1067 (50) 240 (51) 
N1 1195 (46) 986 (46) 209 (44) 
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NX 120 (4) 98 (4) 22 (4) 
        
M0 1109 (42) 909 (42) 200 (42) 
M1 1513 (58) 1242 (58) 271 (58) 
        
Gleason sum score: 
≤7 546 (21) 457 (21) 89 (19) 
8-10 1890 (72) 1529 (71) 361 (77) 
Missing  186 (7) 165 (8) 21 (4) 
    
Hormonal treatment at randomisation:  
Bicalutamide 19 (<1) 16 (<1) 3 (<1) 
GnRH2 2603 (98) 2119 (98) 465 (99) 
Maximum androgen 
blockade 
8 (<1) 8 (<1) 0 (0) 
Orchiectomy 11 (<1) 8 (<1) 3 (<1) 
        
Metabolic Disturbance: 
Hypertension 1466 (56) 1012 (47) 454 (96) 
Diabetes  220 (9) 63 (2) 157 (33) 
Obesity  686 (28) 278 (14) 408 (87) 
Low HDL3 1844 (87) 1384 (83) 460 (99) 
 
1 composite metabolic aberrations  
2 gonadotropin releasing hormone  




Table 28: Hazard ratios for prostate cancer progression free survival for men with 




  HR4 95% CI 
 
  
CMA2 0.97 0.82-1.14 
HBP 1.05 0.93-1.19 
Obesity  0.96 0.83-1.11 
HDL3 0.98 0.80-1.20 
DM  0.94 0.74-1.19 
 
1 adjusted for age, Gleason sum score, PSA pre-ADT, type of ADT and TNM stage.  
2 composite metabolic aberrations 
3 high density lipoprotein 




Table 29: Hazard ratios for time to PSA, local and metastatic progression for men with 





HR4 95% CI 
 
PSA Progression 
CMA2 0.94 0.80-1.11 
Hypertension 1.02 0.90-1.16 
Obesity  0.96 0.83-1.11 
Low HDL3 0.98 0.80-1.21 
Diabetes Mellitus  0.96 0.76-1.22 
 
Local progression 
CMA2 1.61 1.09-2.36 
Hypertension 1.07 0.79-1.44 
Obesity  1.1 0.82-1.63 
Low HDL3 1.65 0.92-2.98 
Diabetes Mellitus  1.11 0.59-2.09 
 
Metastatic Progression 
CMA2 1.23 0.96-1.57 
Hypertension  1.05 0.88-1.26 
Obesity  1 0.81-1.22 
Low HDL3 1.12 0.83-1.52 
Diabetes Mellitus  1.06 0.74-1.51 
 
1 adjusted for age, Gleason sum score, PSA pre-ADT, type of ADT and TNM stage.  
2 composite metabolic aberrations 
3 high density lipoprotein 




Table 30: Hazard ratios for time to all cause death and prostate cancer-specific death for 


























1 adjusted for age, Gleason sum, PSA pre-ADT, type of ADT and TNM stage.  
2 composite metabolic aberrations 
3 high density lipoprotein  





  HR4 95% CI 
All-cause death 
CMA2 0.73 0.38-1.40 
HBP 0.99 0.82-1.19 
Obesity  1.02 0.60-1.72 
HDL3 1.94 0.70-5.40 
DM  1.21 0.55-2.66 
Prostate Cancer Specific Death 
CMA2 0.86 0.38-1.97 
HBP 0.95 0.77-1.18 
Obesity 1.17 0.59-2.33 
HDL3 1.23 0.37-4.11 
DM 0.98 0.30-3.22 
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Table 31: Multivariate Hazard ratios for time to PSA, local and metastatic progression for 
men with baseline metabolic aberrations by metastatic status at randomisation into the 
trial in the STAMPEDE study  
 
 Metastatic disease at 
randomisation n=1,509 





HR3 95% CI 
Event 
No 
HR3 95% CI 
PSA Progression 
 
CMA1 784 0.95 0.79-1.15 221 1.01 0.72-1.43 
HBP 784 0.97 0.84-1.11 221 1.21 0.92-1.60 
Obesity  752 0.96 0.82-1.14 209 1.00 0.74-1.34 
HDL2 631 1.07 0.84-1.36 180 0.81 0.54-1.22 




CMA1 146 1.66 1.08-2.55 46 0.90 0.39-2.09 
HBP 146 1.12 0.80-1.59 46 0.84 0.44-1.61 
Obesity  136 1.48 0.99-2.22 43 0.57 0.28-1.16 
HDL2 111 1.31 0.66-2.59 36 7.31 1.62-32.98 




CMA1 428 1.26 0.97-1.64 73 1.11 0.57-2.14 
HBP 428 1.08 0.89-1.31 73 0.96 0.59-1.57 
Obesity  409 1.028 0.82-1.28 66 1.04 0.58-1.87 
HDL2 345 1.159 0.82-1.63 61 0.96 0.44-2.06 
DM  428 1.114 0.75-1.65 73 0.80 0.34-1.91 
 
1 composite metabolic aberrations 
2 high density lipoprotein  





This study investigated how baseline metabolic aberrations in men with 
localised/metastatic PCa treated with ADT affected outcomes of PCa progression, 
PCSD and death. No difference in PCa progression was observed for any of the 
individual baseline metabolic aberrations or those with CMA. However, when 
examining the different components of PCa progression, men with multiple 
metabolic aberrations at initiation of ADT, here referred to as CMA, had a 
worsening of local progression free survival, as compared to those without 
metabolic aberrations. In a further exploratory analysis, within subgroups defined by 
metastatic status, the difference in local progression was only observed in those 
men with metastatic disease at baseline; there was however no evidence of 
heterogeneity.   Metabolic status was not reliably observed to be associated with 
any difference in OS or PCSD within this analysis, although the number of events is 
fairly modest.  
A study using a smaller US cohort of 82 men with PCa treated with ADT previously 
reported an association between MetS and PSA progression on ADT and OS (86). 
They reported a worsening of time to PSA progression for patients with MetS, 
observing median times of 16 months vs. 36 months for men without MetS (p 
=0.003). The median OS for men with MetS was 36.5 months, compared with 46.7 
months for those men without MetS (p=0.061) (Figure 22). The authors did not 
investigate an association with local or metastatic progression. A further recent 
study of 273 men with biochemically recurrent PCa following radical treatment, 
examined PCSD in men with baseline metabolic aberrations. The authors reported 
no association with PCSD, but did show that men with hypertension tended to have 
a higher cumulative incidence of PCSD compared to those without (HR: 1.59, 95% 
CI: 0.89-2.84). The authors also reported that men with MetS had a worsening of 
time to all-cause death (87). 
There is biological plausibility that men with baseline metabolic aberrations may 
progress more rapidly than those without. MetS is known to be associated with low 
testosterone levels and testosterone replacement therapy has been associated with 
a significant reduction of fasting plasma glucose, triglycerides and waist 
circumference (193).  PCa arising in a low testosterone environment is likely to be 
less sensitive to ADT and other hormonal treatments. Therefore, more rapid 




The findings of this study differ from those of Flanagan and colleagues (86) where 
an increased risk of PSA progression was observed. However, this study shows an 
association with local progression and a trend towards a worsening of time to 
metastatic progression.  No difference for either time to PCSD or all cause death is 
shown. In contrast, Rudman et al (87) showed no association with PCSD, but they 
did report a worsening in time to all cause death. However, the median follow up 
time in this study was only 21 months vs. 11.6 years in that study. The short follow-
up time may explain why a similar worsening in time to all cause death was not 
observed. Furthermore, these data were taken from a randomised controlled trial 
whereby participants were mandated to have a WHO performance status of 0-2, 
representing a selected group of those with better performance status and the least 
co-morbidities. It is clear that the association between metabolic aberrations and 
PCa outcomes is not a simple one. The conflicting results may occur due to the 
heterogeneity in study design and the populations used (194). The definitions of 
metabolic aberrations used and although broadly similar still results in some 
heterogeneity, largely in the lipid and glucose profiles used. This supports the need 
for prospective studies specifically investigating the association between MetS and 
PCa outcomes. 
Strengths of this study are its large sample size and the quality of the data which 
was taken from STAMPEDE, an MRC randomised controlled trial. However, full 
metabolic profiles on patients, including waist hip ratios, full fasting lipids and 
glucose measurements were not routinely collected. Several previous studies have 
validated the use of BMI as a suitable surrogate marker for visceral obesity (195, 
196). The absence of triglycerides and fasting glucose measurements in this study 
is a further limitation. Also, the use of patient reported co-morbidities, such as 
diabetes and hypertension, is not optimal, though they have been used in previous 
studies (87). Furthermore, another potential limitation of this work is that the first 
progression may be better reported than subsequent progressions e.g. local 
progression may be under reported by clinicians, in particular when PSA or 
metastatic progression occurs first. This potential underreporting needs to be 
considered when interpreting the data for local progression. A further limitation is 
that CMA may be induced by the ADT after randomisation and affect disease 
progression. Future studies will benefit from data on development of CMA during 
follow-up. Finally, the median follow-up time in this dataset was fairly short so that 
differences in PCa-specific and all cause death may not yet be identifiable. There is 
potential to repeat this analysis in the future once longer follow up has accrued.  
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Overall, this study highlights the need for further studies which collect full metabolic 
profiles prospectively, allowing longitudinal assessment of MetS as defined by the 
joint statement of major international associations. Since the most recent arm to 
open in STAMPEDE is examining the addition of metformin to standard of care, the 
protocol has been amended to allow prospective collection of a full metabolic profile 
at baseline, as well as serial measurements, allowing future analyses to address 
this important question (197). 
 
Conclusion  
The findings of this study suggest that the metabolic status of a man with PCa may 
be associated with certain poorer disease outcomes. Hence, by actively managing 
these metabolic risks it may be possible to improve these outcomes. Further 
longitudinal prospective studies examining this association are required to 


















Figure 22: Time to PSA progression by metabolic syndrome status taken from paper by 











This chapter describes the Metformin and Longevity (METAL) trial, for which I wrote 
the protocol, all related study documents and gained all necessary approvals prior 
to its opening to recruitment in August 2015.  My involvement has continued as 
both a sub-investigator and the trial coordinator.  This chapter covers the 
background, rationale and design of the trial as well as an update on current 
progress and difficulties in running a ‘window of opportunity’ trial.  The full trial 
protocol and summary of medicinal product characteristics (SMPC) for metformin 
are reproduced in Appendix 5.  Recruitment to the trial is ongoing and so the 
analysis and results of the trial are not within the scope of this thesis.  I have 
presented the protocol of the trial as a poster presentation at the annual conference 
of the ESMO in Copenhagen in 2016 and it has also been published in BMC 
Cancer, July 2017 (Appendix 5).  
Background 
The epidemiological evidence examining the association between metformin and 
PCa risk, mortality and outcomes is summarised in Chapter III. The biological 
mechanisms underlying these potential associations are not fully elucidated (198).  
One hypothesis is that its anti-neoplastic effect may be via an indirect effect of 
insulin lowering, which in turn leads to a reduction in IGF-1 levels. Both elevated 
insulin and IGF-1 levels are known to play a role in PCa development and 
progression (199). However, a host of direct molecular mechanisms has also been 
suggested. These are described below.  
The potential direct molecular anti-cancer actions of metformin are summarised in 
Figure 23 (200). Many of these actions are mediated via 5’-AMP- activated protein 
kinase (AMPK) (Figure 24).  AMPK is an energy sensitising serine threonine 
kinase.  It is made up of three subunits: alpha, beta and gamma. It is a crucial 
enzyme in cellular regulation, with important roles in gluconeogenesis, glucose 
homeostasis and lipid metabolism (201, 202).  AMPK is activated under conditions 
of metabolic stress which leads to intracellular adenosine triphosphate (ATP) being 
depleted and AMP increasing. For AMPK to be fully activated, it requires 
phosphorylation of the alpha subunit. This is mediated by upstream kinases 
including LKB1 (Figure 23/24). Once activated, AMPK inhibits the mammalian 
target of rapamycin (mTOR) and other protein synthesis. These direct effects can 
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lead to reduced cell proliferation (203) and hence exert an anti-cancer effect. 
Metformin is a potent activator of AMPK via inhibition of complex I of the respiratory 
chain, which results in increased AMP (204).  
Once activated, AMPK also inhibits important enzymes involved in lipogenesis, 
including Fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC). FASN is 
an enzyme which plays a role in the conversion of excess carbon into fatty acids for 
storage. It catalyses the conversion of precursors malonyl-CoA and acetyl-CoA into 
palmitate (Figure 25) and is implicated in carcinogenesis  and has been shown to 
be upregulated in PCa (201). A hallmark of most cancer cells is an increase in de 
novo fatty acid synthesis and increased FASN expression has been linked to worse 
outcomes in PCa (205). Several pre-clinical studies have demonstrated that 
inhibition of FASN results in cell death in PCa cell lines (206). 
It is suggested that metformin may also act via AMPK- independent mechanisms.  
These  include inhibitory effects on extracellular signal–regulated kinases  (ERK), 
nuclear factor kappa-B (NF-KB) and preventing tumour growth by preventing p53-
induced autophagy (201).  
 
Despite a wealth of preclinical work examining metformin’s action on PCa, there is 
very limited data from human studies in PCa.  A Canadian Phase 2 ‘window of 
opportunity’ study evaluated the effects of metformin on PCa focusing on the AMPK 
pathway in paired pre-treatment and prostatectomy specimens (207).  22 patients 
of a planned 40, were given metformin in a dose escalation regimen from 500mg 
daily to 500mg three times per day prior to their prostatectomy.  They had 
difficulties with recruitment and slow accrual and the trial was closed early due to 
these issues. The median duration of treatment was 41 days.  Although the study 
was limited by small sample size and lack of a control arm, a change in the 
proliferation marker ki67 was observed following metformin therapy (mean 50% 
reduction). However, in this small study no change in pAMPK was observed. The 
study also demonstrated the safety and feasibility of metformin therapy in this 
patient group. To our knowledge this is the only clinical trial, with published results, 
which has specifically examined the molecular actions of metformin in the PCa 



















A potential role for metformin in PCa has thus been suggested and given its wide 
availability, tolerable side effect profile and safety record it may represent a 
therapeutic option for men with PCa. However, as described above, the mechanism 
of action by which metformin exerts its anti-cancer effect has yet to be 
characterised. Thereby I designed a ‘window of opportunity’ trial that investigates 
this by comparing baseline prostate biopsies with post-treatment surgical 
specimens focussing on assessment of the FASN/AMPK axis. The study has a 
placebo arm in order to provide a control group.  
 
Risk/benefits 
The usual timing between diagnostic biopsy and prostatectomy is between four and 
six weeks, so participation in the study does not delay surgery. Since this is a proof 
of principle trial with a relative short duration of treatment, it is unlikely that patients 
will derive significant benefit by study participation. However, it has been shown 
that metformin is well tolerated in a non-diabetic population (207) and it is not 
anticipated that patients will experience increased morbidity by participating in the 
study. 
 
Objectives and trial summary  
METAL is a randomised, placebo-controlled, double-blind, window of opportunity 
study investigating the biological mechanism of metformin in PCa. Window of 
opportunity studies are designed to test one or more new treatments in the period 
between the patient’s cancer diagnosis and them receiving their standard 
treatment. The treatment being received normally has curative intent, in this trial a 
radical prostatectomy, and the patients are therefore normally treatment naïve 
(208).  Early stage patients eligible for prostatectomy were chosen, rather than later 
stage patients, as this study has a biological endpoint and requires tissue, which is 
not always available from patients with later stage disease.  
 
100 non diabetic patients with newly-diagnosed, early stage PCa scheduled for 
radical prostatectomy will enter the main study and are randomised 1:1 to receive 
metformin (2g daily over 2 divided doses; Arm A) or placebo four weeks prior to 
prostatectomy (standard of care; Arm B).  A subset of five patients (due to financial 
constraints) will enter the exploratory positron emission tomography–magnetic 
resonance imaging (PET-MRI) sub study.  These five patients will all receive 
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metformin and will undergo an additional two PET-MRI Scans (see below).  See 
Figure 26 for the trial schema and Figure 27 for the trial flow chart.  
 
The trial objectives and primary, secondary and exploratory endpoints are 
summarised in Table 30.  The primary objective of this study is to investigate the 
biological mechanism of metformin on PCa using pharmacodynamic markers. The 
primary endpoint for this study is therefore the difference in expression levels of 
biomarkers representing the FASN/AMPK pathway for the metformin and placebo 
groups, as measured by the H score.  
Secondary endpoints include the difference in indicators of proliferation in the same 
groups, as well as differences in expression levels of the biomarkers between 
benign and malignant tissue (Table 30).  
Following informed consent and screening, patients in the main study are 
randomised and continue metformin or placebo for four weeks until the evening 
prior to radical prostatectomy. In the event that surgery is scheduled for after this 
time point, patient will continue study drug for an additional one week.  
Formalin fixed paraffin embedded tissue will be collected from baseline diagnostic 
biopsy and from the prostatectomy. Tissue will then be shipped to Centre for 
Molecular Oncologic Pathology (CMOP) at Dana Farber Cancer Institute (DFCI). 
The following analyses will be conducted at the CMOP on collected baseline and 
post-surgery tissue specimens: 
• p-AMPK, p-ACC, FASN, ki-67 and Terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL) will be assessed in benign and malignant 
tissue by immunohistochemistry using image analysis. 
• The ki-67 proliferation index is assessed by point counting 1000 cells, and is 
reported as percent positive cells.  
 
TUNEL is an apoptotic index defined as the number of apoptotic cells per 1000 
tumour cells. 
Remaining markers will be measured using a H-score.  The H score is a way of 
quantifying the immunohistochemical staining of a section.  Membrane staining is 
subjectively rated as an intensity (0, 1+, 2+, or 3+) which is determined for each cell 
in a fixed field.  In one commonly used method, the percentage of cells at each 
staining intensity level is calculated, and finally, an H-score is assigned using the 
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following formula: [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]The final 
score ranges from 0 to 300.  In this way more relative weight is given to higher-
intensity membrane staining.  The sample can then be considered positive or 
negative based on a pre-defined threshold (209). Methods for these analyses have 
been optimized and used in preliminary studies performed at CMOP. Tissue 
(prostate) metformin concentrations will also be performed. Details of these 
analyses lie outside of the scope of this thesis. 
 
The primary endpoint of this study is pharmacodynamic and therefore time between 
study drug dose and prostatectomy is an important factor. To minimise the effects 
of dose reductions and interruptions, the primary endpoint analysis will be based on 
a per protocol analysis. Evaluable patients are defined as: 
- Received at least 21 days (three weeks) of study drug between 1.5-2.0g daily.  
- Received study drug uninterrupted for the last seven days prior to prostatectomy.   
A secondary analysis will include an intention-to-treat analysis.  
Following prostatectomy, all patients will be followed up for a final safety.  Following 
this visit, patients do not require further study-related follow up and will continue to 
receive standard of care. 
Exploratory Sub-study 
The exploratory endpoint of this study involves 18F Choline PET/MRI evaluation at 
baseline and post-metformin (pre-prostatectomy) for assessment of response in 
prostate tissue.  Both PET and MRI are now well established in the diagnostic 
pathway for PCa (32) and there is a rationale for combining the two modalities to 
improve diagnostic accuracy, however this remains experimental at present (210, 
211). This exploratory sub-study will include five patients with MRI positive disease, 
not randomised in the main trial, all of whom will receive metformin. Apart from the 
additional two visits for the 18F Choline PET/MRI scans, they will follow the same 
trial protocol/ visit schedule as those in the main study (Figure 27).  The criteria for 
enrolment in to this sub study are: 
1. Patient willing to undergo two additional PET-MRI scans  
2. MRI positive disease 
3. Satisfactory completion of MRI safety questionnaire 
4. Availability of 18F Choline and scanning slots which would not result in a delay to 
the patient’s enrolment into the study or to their surgery 
No patients have yet been recruited to this sub study, recruitment is planned to 




The trial is currently open at three tertiary referral hospitals in the UK. 
• Guy’s and St Thomas NHS Foundation Trust  
• Royal Marsden NHS Foundation Trust  
• Royal Gwent Hospital  




Patients eligible to participate in this study are those who meet all of the following 
inclusion criteria: 
1. Age 18 or older and willing and able to provide signed informed consent. 
2. Histologically confirmed adenocarcinoma of the prostate, with a maximal 
tumour length of greater or equal to 6mm on core biopsy 
3. No previous treatment for prostate cancer (including surgery, any hormone 
therapy, radiotherapy and cryotherapy) 
4. Prostate biopsy within 6 months from screening  
5. Radical prostatectomy is the scheduled treatment of choice 
6. Eastern Cooperative Oncology Group (ECOG) Performance status less than 
or equal to 0 or 1 
7. Adequate organ function, defined as follows: 
 Haemoglobin >10.0g/dL 
 Absolute neutrophil count >1.5x109/L 
 Platelet count >100x109/L 
 Renal function, eGFR >60ml/min (calculated by Cockcroft Gault) 
 AST and/or ALT <2.5 x ULN 
 Total Bilirubin <1.5 x ULN 
8. Able to swallow the drug and comply with study requirements.  
 
Exclusion Criteria:  
Patients must NOT meet any of the following exclusion criteria:  
1. Patients with a current or historical diagnosis of type one or two diabetes 
and/or have ever received metformin 




3. History of or conditions associated with lactic acidosis such as shock or 
pulmonary insufficiency, alcoholism (acute or chronic), and conditions 
associated with hypoxaemia 
4. Patients with chronic liver disease, severe cardiovascular impairment, 
cardiac failure, recent myocardial infarction, severe peripheral vascular 
disease or renal impairment (eGFR <60ml/min as measured by Cockcroft 
Gault) 
5. Patients with acute severe disorders, for example infections with fever, 
pancreatitis, trauma, dehydration or reduced diet (<1000kcal or 4200kJ per 
day) 
6. Other active malignancy over the last five years that has required systemic 
therapy, excluding: 
a. Adjuvant therapy in the curative setting 
b. Non-melanoma skin cancer 
c. Superficial transitional cell carcinoma (CIS-T1) 
7. Current enrolment in an investigational drug or device study or participation 
in such a study within 30 days of signing consent. 
8. Any subjects who is able to father a child and does not agree to use barrier 
protection, in the form of a condom, for the duration of the trial and for 16 
weeks after the last study drug administration. 
. 
Sample size  
The primary analysis for this study will quantify the difference in expression levels of 
biomarkers representing the FASN/AMPK pathway, as well as indicators of 
proliferation, for the metformin and placebo groups as measured by the H score 
using a simple two-sample t-test. Secondary analyses will include a comparison of 
differences in expression levels of biomarkers of the FASN/AMPK pathway, as well 
as indicators of proliferation, between benign and malignant tissue.  Finally, we will 
perform a multivariate regression analysis to predict effects of metformin on 
expression levels using tumour and patient-specific characteristics.  
 
Our original sample size calculation was based on the H-score used to assess 
expression levels of the studied biomarkers, which ranges from 0 to 300. We 
conducted a two-sided test (alpha=0.05; power=0.80) comparing the mean 
difference in the two groups for different scenarios as we will be testing different 
biomarkers. Based on these scenarios, we planned to recruit 90 patients for each 
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arm over a period of 15 months.  However, since the start of the trial we have also 
identified other pathways to be studied in the prostate tissue. Moreover, we will set 
up a stratification trial following the biological information obtained in this trial. As a 
result we have reviewed our sample size calculation by increasing the type I error to 
20% - which will require us to only recruit 50 men in each group. As we will conduct 
a follow-up trial with a clinical outcome, the potential type I error can be corrected 
for in this second trial. At the current stage it is thus more important to reduce the 
probability of failing to reject the null hypothesis when it is false. Hence, we have 
not changed the power in our revised sample size calculation. Table 31 below 
shows the revised power calculation. In addition to the 50 patients in each arm, we 
will recruit an additional five patients in the exploratory endpoint group who will not 































Figure 27: METAL trial flow chart 
Phase Screening Pre-surgery Treatment Surgery Post-surgery 


















Informed consent X      
Eligibility review X X     
Randomisation  X     
Medical History1 X      
Demographics X      
Physical Exam X X x x  x 
Vital signs2 X  x x  x 
ECOG PS X X x x  x 
Height X      
Weight X   x  x 
Waist/Hip ratio X   x  x 
Haematology X  x x  x 
Biochemistry3 X  x x  x 
Fasting Glucose/Lipids X   x   
PSA and Testosterone X   x  x 
HbA1c X      
Whole blood and Serum 
save4  
X   X   
Study Drug 
Administration 
 X x x   
Medication review X X x x  x 
Compliance evaluation 
(diary and verbal) 
  x x   
Adverse events (CTCAE 
v4) 5 
 X x x  x 
Paraffin embedded 
tissue sent to laboratory 
X    x  
Prostatectomy     x  
MRI safety assessment7 X      







1. Full medical history, including history other disease, active or resolved, concomitant illnesses 
and cancer diagnosis. 
2. Blood pressure, pulse rate and oxygen saturation, BM 
3. Renal profile, liver function tests, bone profile  
4. To be taken at selected sites only and  according to the Trial specific SOP 
5. Clavien Dindo assessment to be completed at 8-10 weeks post operatively 
6. This review will coincide with routine post-operative review 









Primary endpoints   
 To determine the biological effect of 
metformin on markers of the 
FASN/AMPK pathway in prostate 
tissue by comparison of pre and post-
treatment samples. 
Assessment of the difference in expression 
levels of markers of the FASN/AMPK pathway 
pre and post treatment between the placebo 
and metformin arms. 
Secondary endpoints   
To evaluate the biological effect of 
metformin on markers of proliferation 
in prostate tissue by comparison of 
pre and post-treatment samples. 
Assessment of the difference in expression 
levels of indicators of proliferation (ki67 and 
TUNEL) pre and post treatment between the 
placebo and metformin arms. 
To evaluate differences in 
FASN/AMPK-associated markers in 
benign and malignant prostate tissue. 
Assessment of the difference in expression 
levels of markers of the FASN/AMPK pathway 
and indicators of proliferation between benign 
and malignant prostate tissue in the placebo 
and metformin arms. 
To measure metformin levels in 
prostate tissue. 
Assessment of the difference in metformin 
levels in baseline and post-treatment prostate 
tissue. 
To determine safety of metformin in 
this non-diabetic patient cohort. 
Assessment of adverse events and laboratory 
evaluations. 
To determine surgical toxicity. Assessment of surgical-specific toxicities: time 
between biopsy and surgery, peri-operative 
bleeding, infection, rectal injury and length of 
hospital stay. 
Exploratory Objectives and Endpoints   
To evaluate the effects of metformin 
on functional imaging of the prostate. 
Difference in 18F Choline PET/MRI between 
baseline and post-treatment (prior to 
prostatectomy) in a separate non-randomised 




Table 33: Sample size calculation (two-sided test with power=0.80) to identify mean 
difference in H score between biopsy and radical prostatectomy specimen for the 





















Scenario 1 15 (35) 0 (35) 86 38 50 
Scenario 2 30 (65) 0 (65) 74 59 43 
Scenario 3 20 (25) 5 (25) 44 35 26 
Scenario 4 30 (50) 5 (50) 63 50 37 
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Trial progress and difficulties  
Set up and opening  
METAL is a Clinical Trial of Investigational Medicinal Product (CTIMP) and the set 
up and opening has followed a strict framework with well-established legal 
requirements and authorisations. The process is summarised in Figure 28 below. I 
began work on the trial set up in October 2014.  Working closely with all 
collaborators and investigators, I wrote the trial protocol (Appendix 5), laboratory 
manual, data management plan, case report form, patient information sheet, 
informed consent form and a compliance diary. I also worked with the PCa data 
manager to create a trial database using Microsoft Access.  The trial was registered 
with EudraCT and clinicaltrials.gov.  I successfully gained Research ethics 
committee (REC), Medicines and Healthcare products Regulatory Agency (MHRA), 
Administration Radioactive Substances Committee (ARSAC) and NHS Research 
and Development (R&D) approval. The study opened for recruitment at Guy’s and 
St Thomas NHS Foundation Trust on 04/08/2015. The first patient was randomised 
on 01/09/2015.   
Our first milestone (Table 32) was to finalise ethical and R&D approval and was 
due to be completed by March 2015.  This was achieved, but with a 5 month delay. 
There were various reasons for this.  REC approval was granted on the 31st March 
2015 and MHRA approval on the 23rd March 2015. Each submission had 
recommended different minor alterations, so it was necessary to submit substantial 
amendments to both boards to combine the changes. Hence, final approval from 
both was not received until May 2015 due to amendments not being handled in the 
same time frame as initial applications.  Concurrently, I had applied for local R&D 
approval in February 2015, but this was not received until May 2015. This 
constituted a major delay to opening. This was due partly to the delay with REC and 
MHRA approvals explained above. This was then further delayed by the amount of 
internal review boards through which it had to pass, some of which only meet 
monthly. Finally, once R&D approval had been issued on 18/06/2015, there was a 
further four week delay due to a problem in the pharmacy manufacturing unit. This 
resulted in the investigational medicinal product (IMP) not being ready and opening 
was hence delayed until the beginning of August. 
Accrual and Duration of Study 
The next milestone was the recruitment of 75 patients by October 2015. As 
described above, due to delays in the opening of the trial, the first patient was not 
recruited until 01/09/2015. The initial estimated accrual for the study was 10 
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patients a month. Allowing for a 5% drop out rate, patient accrual was expected to 
be completed within 18 months. 
 
However, once open, recruitment has been substantially slower than predicted. 
Figure 29 shows monthly recruitment at Guy’s and St Thomas NHS Foundation 
trust from opening until August 2017.  At the time of writing the trial had recruited a 
total of 40 patients across all sites. To August 2017 over 350 men had been 
screened as potential candidates for the trial. The reasons behind the slow 
recruitment are complex and multifactorial and have changed over time.  Some of 
the particular issues encountered during recruitment to the METAL trial and actions 
taken to rectify them are summarised below:  
 
1. Eligibility was limited to those with an original biopsy specimen at our site 
but this did not yield enough cases.  An amendment was submitted to allow 
recruitment regardless of biopsy origin, allowing both local and tertiary 
referred patients to be recruited. 
2. In order to be eligible the biopsy had to be within 8 weeks of consent.  This 
was amended to 12 weeks and subsequently 6 months in further 
amendments.  This allows both patients who defer surgery for personal 
reasons or those on AS who may not have had a recent biopsy, but have 
upgraded on MRI, to be recruited.  
3. Further sites to boost recruitment have been added. King’s College Hospital 
was added as a patient information site, so that patients seen there but 
whose surgery occurs at Guy’s hospital can be approached. A second site 
at the Royal Marsden opened to recruitment in December 2015.  However, 
due to a variety of staffing issues and competing trials, they have to date, 
only recruited two patients. Finally, a third site has opened to recruitment in 
September 2017 at the Royal Gwent hospital, Newport, Wales. At the time 
of writing they had yet to recruit their first patient. 
 
The difficulties of recruiting to this kind of ‘window of opportunity study’ have been 
discussed elsewhere (208) and other trials with a similar design have also 
experienced problems with recruitment, some having to close early due to slow 
accrual (207).  Whilst the benefits of this design of trial include the ability to test 
novel compounds in treatment naïve patients with access to pre and post treatment 
biopsy or surgical specimens, some of the weaknesses of this design, contribute 
directly to the recruitment difficulties which we have experienced. In this design, the 
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length of treatment is usually very short to avoid any delay to the proposed 
standard, definitive treatment which in most cases has curative intent. Due to this 
short duration and the testing of novel agents it is unlikely that individual 
participants will gain benefit from the intervention and hence makes it unethical to 
delay a patient’s standard treatment to allow participation. This means that these 
trials are difficult to run logistically as time between diagnosis, treatment decision 
and definitive treatment can be short in many centres.  
 
The future 
Despite the difficulties in recruitment, all investigators remain committed to 
completing this important trial exploring the biological mechanisms by which 
metformin affects PCa, which still remain to be fully elucidated.  Additional funding 
has been secured from the Guy’s and St Thomas Hospital Charity to allow 
recruitment to continue for a further two years, until September 2019. The addition 
of a further site at the Royal Gwent and a push in recruitment at the Royal Marsden 
combined with continued steady recruitment at Guy’s and St Thomas’ mean that we 





















































































































































Finalise Ethical and R&D approval  X   
75 patients recruited and data/tissue before and after exposure collected  X  
Completion of tissue staining and comparison    X 
Completion of analysis of PET/MRI scans for subset of patients   X 
Complete statistical analysis of association between metformin and 
tissue markers 
  X 
Complete statistical analysis of quality of life outcomes before and after 
exposure 







Chapter VII: Final remarks and Future Direction 
 
The prevalence of T2DM is rising worldwide and its onset is occurring earlier in 
patients’ lives. This coupled with improvements in PCa survival ensures that the 
interplay between these two conditions will only become increasingly important in 
the years to come.  Nevertheless, aspects of the relationship remain relatively little 
studied. This thesis serves to highlight this and hence can act as an outline for 
future research.  
 
The explanation behind the inverse association reported in Chapter II between pre-
existing T2DM and PCa incidence is far from clear. Further work within PCBaSe to 
explore potential explanations for this inverse association are now being planned 
including: a potential peak in PCa diagnostic activity around time of T2DM 
diagnosis, time since diagnosis of T2DM, age at time of DM diagnosis and PSA 
density in those with T2DM. I will apply for a lectureship to continue this work on the 
interaction between T2DM and PCa. 
 
Furthermore, the impact of PCa on T2DM glycaemic control and management has 
not been widely studied. Further prospective studies in which the impact of both 
PCa and its treatments, are needed to corroborate the findings presented in 
Chapter IV of this thesis.   
 
The impact of metabolic disturbances, including T2DM, on clinical outcomes in PCa 
also remains to be elucidated. Though early studies suggested that the presence of 
MetS had a negative effect on outcomes, such as time to PSA progression, 
subsequent work has failed to corroborate this. Further prospective studies with full 
baseline metabolic parameters and serial measurements throughout the treatment 
trajectory of men with PCa are needed. In light of the many new treatment options 
for PCa, it would also be interesting to assess the impact of a man’s metabolic 
status on response to these treatments, both individually and also in the particular 
sequence in which they are received. As part of my lectureship application, I am 
therefore also planning further studies similar to the one presented in Chapter V, 
using data from the different treatment arms in the STAMPEDE trial including those 
treated with docetaxel chemotherapy and Abiraterone.  
 
Finally, the mechanism of action of metformin in PCa is still unknown. To be able to 
use metformin most appropriately and potentially target patients who will gain the 
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most benefit from its use in the future, this fundamental understanding of its 
underlying mechanism of action will be paramount. The results of the METAL trial, 
once completed, should therefore help to guide future such stratification trials and 
research.  
 
In conclusion, this thesis highlights the complexity of the interplay between T2DM 
and PCa, in which both conditions impact on both the treatment and disease 
outcomes of the other.  Much of this interplay is still not fully understood and further 
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